crohn's and colitis foundation of america annual report
TRANSCRIPT
VoicesO F P R O G R E S S
A N N U A L R E P O R T2 0 0 8
To cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.
Our Mission
Table of Contents
1Table of Contents
Crohn’s disease and ulcerative colitis are exceptionally complex diseases in-volving the human immune system and gastrointestinal tract. Understandingthe biological underpinnings of IBD requires research in the scientific fields ofimmunology, microbiology, biochemistry, and genetics, which have all beentargeted by CCFA in our strategic plans and grant programs. The Foundationfunds cutting-edge, multi-disciplinary studies at major medical institutions,nurtures investigators at the early stages of their careers, and finances un-derdeveloped areas of research.
There has never been a more hopeful time to investin IBD research.
President’s Letter 2
Research Report 4
Research Awards 10
Financial Statements 20
Friends of CCFA 26
President’s Corporate Circle 33
Founders Society 34
Our Chapters 36
Leadership & Staff 38
Fiscal 2008: September 1, 2007 — August 31, 2008
Crohn’s disease and ulcerative colitis, known collectively as inflammatorybowel diseases (IBD), are painful, medically incurable digestive diseases. Ap-proximately 1.4 million Americans are afflicted, including over 140,000 chil-dren. Most often striking young adults, IBD exacts a heavy toll in acute care,and can often involve multiple surgeries, hospitalizations, and in rare cases,untimely death. Although we have made significant progress in treating Crohn’sdisease and ulcerative colitis in recent years, we do not yet have cures or meansof prevention.
About Crohn’s disease and ulcerative colitis
2008 was a watershed year for our Foundation.We reached new fundraising and research mile-stones. In the past fiscal year, we invested $15.5million in research, roughly two and a half timeswhat we allocated only a couple of years ago. CCFAfunded fifty-three research projects this year, an excellent accomplishment in what continuesto be a financially challenging environment.
CCFA has defined itself by sponsoring the bestand brightest researchers over many decades,seeding the field with studies around the mysteries
of Crohn’s disease and ulcerative colitis, collec-tively known as inflammatory bowel diseases(IBD). The model has been a resounding successas the majority of our selected scientists have received continuing grants from the National Institutes of Health to undertake larger and moredefinitive studies. This strategy has resulted in a very high return on our invested dollars. It alsohas shaped a strong partnership with the researchcommunity that was most apparent in this year of financial challenges.
Dear Friends,
There has never been a time to be more committed to the cause of life-changing research in Crohn’s disease and ulcerative colitis. Because of your generous support,we are now witnessing astonishing advances in the understanding of these devastat-ing diseases that inflict such a heavy burden on thousands of families.
Forty-two years of Foundation history have demonstrated the power of our donors’unwavering support. Over four decades, CCFA has become the unmistakable voice forfinding answers that will one day lead to a cure. The opportunities have never beengreater for transforming the future of over 1.4 million Americans and future generationswith Crohn’s disease and ulcerative colitis by investing in cutting-edge research.
Voices of Progress
President’s Letter
3Due to our accelerated research investment in the pastyear, our portfolio can now boast of two high-profileinitiatives. In 2008, the Foundation commenced fund-ing of the CCFA Human Gut Microbiome Initiative andthe CCFA Risk Stratification Initiative of our PediatricNetwork. These groundbreaking studies, discussedin this annual report, leverage 21st-century scientificand technology breakthroughs to move us forward inour understanding and treatment of IBD. These invest-ments are aligned with our strategic goals of address-ing areas of unmet needs for solving the puzzle of IBD,and improving the outlook for all young IBD patientsby developing a better standard of care from day one.
The CCFA Human Gut Microbiome Initiative movedfrom a pilot phase into its first and second phases of research in 2008. Dr. Jeffrey Gordon and Dr. RobKnight have now published five scientific articlessharing new information with the worldwide scientificcommunity. The goal of this prestigious undertakingis to develop labor- and cost-effective tools andframework to enable more scientists to study IBD,which can take the field to a new level of understand-ing of the role of intestinal microbes.
Children have always been at the forefront of the con-cern of our Foundation. In 2008, CCFA adopted a newacronym, Pro-KIIDS (Pediatric Resource Organizationfor Kids with Inflammatory Intestinal Digestive Dis-eases) to symbolize our comprehensive and ambitiousapproach to pediatric research and care. CCFA has todate invested over $10 million in research, services,and education programs for young IBD patients.
CCFA’s Clinical Alliance has made impressive headwayin gaining timely information about pregnancy andIBD. However, many more promising studies lookingat clinically important questions are waiting in thewings. The work of the Clinical Alliance is crucial because it both provides short-term improvements inpatient care and a foundation for applying scientificdiscoveries to patient-based research.
The need for patient support has always been at thecore of CCFA’s mission. The rapid uptake in Web-basedtechnology has transformed the field of patient edu-cation and support. CCFA’s Information ResourceCenter (IRC) in its second year launched a communityinteractive Web site that has drawn over 356,000 visi-tors. For our younger patients, our new teen Web site—ucandcrohns.org—provides an online resource secondto none. The IRC has also discovered an appreciativeaudience for educational teleconferences and Webcastsand we will be expanding this activity in the future.
CCFA’s signature fundraising events launched in 2008,Team Challenge— a half marathon and training pro-gram, and Take Steps—a community walk, are provingto be strong contributors to the bottom line. Over30,000 people participated in these events in 2008,raising $9.5 million dollars. We expect that our entryinto the popular social networking site, Facebook,will help drive awareness in FY09. Members will beable to share the cause with networks of friends andcolleagues with ease and efficiency.
Our advocacy efforts in Washington, D.C. are alsosupported by online grass-roots strategies for gainingsponsorship for our IBD bill in Congress. In 2008,support continued to grow. In FY08, NIH funded $80million in IBD research. The NIDDK is the primary sitefor IBD research and responsible for the InflammatoryBowel Disease Consortium. The historic discovery oftwenty-one new disease-associated genes publishedin 2008 was the result of their groundbreaking research. We anticipate that the increase of fundingfrom the economic stimulus in FY09 will continue toincrease the discoveries in genetic research.
This is an exciting time to continue our journey towardcuring and preventing Crohn’s disease and ulcerative colitis. The opportunities that we can pursue todayare significantly more promising than they were onlyten years ago. The potential for efficiencies and pro-ductivity based on digital technology is also most encouraging. We recognize our responsibility to you,our generous supporters, to continue to make thebest choices in research and fundraising programs.We acknowledge that every donation has moved usahead in this long and enduring mission to find a cure.
Sincerely,
Richard J. Geswell Gary SinderbrandPresident Chairman of the
National Board
For basic science and clinical research, a time to be hopeful.
Research Report
Since its inception over forty years ago, CCFA has funded more than 1,100 grants tothe most promising researchers in this field. Our cumulative investment of over $136 million has defined these inflammatory bowel diseases and transformed theclinical management and scientific understanding of Crohn’s disease and ulcerativecolitis. With the convergence of life science breakthroughs, rapid technological advances in genetic research, and our expanding knowledge of the human gut microbiome, our research dollars can bring us closer to curing or preventing thesediseases in more ways than we ever imagined.
Research Report
5Research Highlights
CCFA’s National Scientific Advisory Committee andResearch Department allocates the Foundation’sgrants according to the priorities set in “Challengesin IBD Research,” the Foundation’s strategic plan forresearch programs. The priorities are determinedthrough continuous reassessment of unmet needs,as science and technology evolve. In 2008, expansionof research support into the areas of the gut micro-biome and genetics exemplified the dynamic processof funding research.
CCFA Major Research Priorities• Genetics/Immune Profiles/Biomarkers
for Prognosis— Clinical research• Microbiome— Basic research• Identification of New Genes and Functional
Analysis of Genes — Basic research• Translation of Discovery to Therapy—
Clinical research• Immune Cells/Innate Immune Mechanism —
Basic research• Epithelial Cells/Innate Immune Mechanism —
Basic research• Adaptive Immune Response— Basic research
The Value of Partnership Through its research grants, CCFA has nurtured andhelped focus the careers of many leading investigatorsin IBD. These opinion leaders often began their careersas CCFA research fellows.
A unique turn of events in 2008 illustrates the excep-tional partnership between the Foundation and theresearch community. With the economic downturn already making itself felt, CCFA received a vital boostin grant funding when new and returning senior re-searchers returned 10% of their grant funds to CCFA.
Through this uncommon gesture of support, theFoundation was able to maintain its funding of 25-30% of research applications received from young
investigators. The CCFA community of researchers understands that the continuity of progress towardour common goal requires that we maintain a pipelineof scientific talent.
CCFA’s strategy has produced a windfall of discoveryin this field. The Foundation provides seed funding to the most promising researchers, who subsequentlyapply for continuing funding from NIH to expand theirpilot work. The success of our process is validated by the fact that over 80% of grant recipients receivefunds from NIH to continue their work begun withCCFA support.
Progress in Basic Science
Genetic ResearchIn 2001, the first gene associated with Crohn’s diseasewas identified. In 2008, the number of genes identifiedand associated with IBD more than tripled, from elevento an astonishing forty loci. CCFA-funded researchwas prominent in top scientific journals like Nature,Nature Genetics, and Cell.
Facts• Each year, our National Scientific Advisory
Committee conducts peer review of over 250applications for grants.
• In 2008, the Foundation set a new record,more than doubling its research grants fromonly two years ago.
• Over 80% of CCFA grant recipients receive further funding from NIH to expand their IBD research, validating our grant selectionprocess.
Research investmentsin the past four years: 2005: $6.3 million
2006: $10 million2007: $13 million
2008: $15 million
2009 and beyond
CCFA Human Gut Microbiome InitiativeMajor discovery in science and medicine often comeswhen big and bold new ideas take root and have highimpact. Recent technology breakthroughs have elevatedthe field of metagenomics, the study of the genes ofmicrobes, to a new level. Taking the study of IBD tothe forefront of metagenomics, the Foundation initi-ated its largest multi-year research investment in itshistory in 2008. The CCFA Human Gut Microbiome Ini-tiative, based at the world-renowned Genome Centerof Washington University in St. Louis, is under theable direction of Dr. Jeffrey I. Gordon of WashingtonUniversity, a gastroenterologist and Director of theCenter for Genome Sciences, and Dr. Rob Knight, As-sistant Professor of Chemistry and Biochemistry atthe University of Colorado, an expert in bioinformatics.
Through this initiative, the Foundation is aiming to empower more scientists to study the intestinalcommunity of microbes is are believed to play an intrinsic role in the inflammatory bowel diseases. The research team will create accessible tools andtechniques that can be shared with the IBD scientificcommunity around the world. In essence, CCFA isseeding the research field for future accomplishmentsin the field of IBD.
In conjunction with CCFA’s Clinical Alliance, the humangut microbiome researchers plan to study identicaland non-identical twin pairs, with and without IBD, to further the understanding of human genetics andenvironment in the development of IBD.
Scientific publications resulting from this ground-breaking research began to appear in journals in2008 and shall continue over the next several years.It is anticipated that the resulting insights into intestinal bacteria and their genes will create newleads for tackling the complexities of IBD.
Progress in Clinical Research
A strategic objective of CCFA is to target novel thera-peutic approaches through clinical research that benefits patients in the short term. CCFA’s Clinical Alliance and Pediatric Network unite medical profes-sionals from all over the country to make it possiblefor us to realize this critical goal.
Dr. Bruce Sands, Acting Chief of the GastrointestinalUnit at the Massachussetts General Hospital inBoston and Chairperson of the CCFA Clinical Alliance.“We can utilize established sites to build patient registries or to develop clinical trials. Researcherswould like to look at what treatment works best forindividual problems, side effects, and the best orderof using drugs. Importantly, our work is free of commercial bias.”
CCFA’s Clinical AllianceThe Clinical Alliance may well be the only multi-centerassociation for IBD in the world to be initiated andsupported by a patient-based foundation.
“In time, for example, microbes may become 21stcentury biomarkers of disease risk and a treatment’seffectiveness. New treatments may emerge as re-searchers begin to understand how bacteria attachedto the intestinal lining are exposed to our immunesystems. It should become possible to influence thestructures and operations of our gut communities,and how these communities communicate with ourimmune system.”
Jonathan Braun, M.D., Ph.D., 2005–2008 Chair of CCFA’s National Scientific Advisory Committee
Research Report
7The Alliance was created under the premise that thestudy of a somewhat uncommon disease like IBD requires multiple clinical sites to produce sufficientdata for productive investigations. Although most ofthe forty-six Alliance members are academic medicalcenters, community-based medical practices alsoparticipate.
Pregnancy and IBDCurrently, the major initiative of the Alliance is in thearea of pregnancy and infant health. It is seeking toanswer one of the top questions of all newly diagnosedpatients: the impact of IBD and current therapies onpregnancy and outcomes. This is a question for whichphysicians have only had partial answers at best.
In 2008, this initiative, known officially as The NationalProspective Pregnancy Registry in Inflammatory BowelDisease, made significant advances. Led by Uma Ma-hadevan-Velayos, M.D., at UCSF in San Francisco, theregistry began in August 2007 and has enrolled 350pregnant patients with Crohn’s disease, ulcerativecolitis, and indeterminate colitis at thirty Clinical Al-liance sites. Preliminary results were presented at theannual Digestive Disease Week meeting in June 2009.
If you ask Dr. Mahadevan-Velayos why a pregnancyregistry is an idea whose time is now, she is quick torespond: “Without the registry, we will never be ableto advise women on the effects that their illness andmedications might have on pregnancy outcome andthe baby.”
The pregnancy registry exemplifies how a multi-center collaborative effort can yield information notavailable from single institutions. With the advent of new biologic treatments for IBD, there is a criticalneed for more current information for patients intheir reproductive years. With the pregnancy registry,we can now hope to have better answers.
In the short term, with additional financial investment,the Clinical Alliance can do more to help physiciansand their patients manage IBD more effectively.
The CCFA Pediatric Network and the Pediatric RiskStratification InitiativeFollowing our Pediatric Challenges Plan—laid out in 2006—the Foundation is addressing unmet needs in pediatric research and patient care. In 2008, webegan to identify our diverse initiatives under theacronym, PRO-KIIDS (Pediatric Resource Organizationfor Kids with Inflammatory Intestinal Digestive Diseases).
Most physicians and scientists see prevention of theonset of IBD as the greatest opportunity for eradicatingCrohn’s disease and ulcerative colitis. For the morethan 140,000 children afflicted in the United Statesalone, the need for prevention is even more pressing,as IBD in its most severe forms can irreversibly affectbone development and retard growth. The CCFA RiskStratification Initiative has been set up to “crack thecode” of disease prognosis by identifying measurablerisk factors for the complications of severe disease.In 2008, a very committed group of clinical researchersin CCFA’s Pediatric Network laid the foundation foridentifying genetic, microbiological, and immunologicalfactors that are predictive of more severe diseasewithin several years. The resulting knowledge willtranslate into new protocols for individualized ap-proaches to treating IBD in children — based on theirrisks — and thus preventing severe disease and itslifelong consequences.
In 2008, CCFA Funded:• 53 new research projects
• 200 active grants
The Pediatric Network plans to bring hundreds of pediatric gastroenterologists and other healthcareprofessionals from about 40 pediatric centers (USAand Canada) under its administrative umbrella in aclinical research project of unprecedented scope. TheNetwork is chaired by Dr. Subra Kugathasan, Directorof Pediatric IBD at Emory Children’s Center and Chil-dren’s Hospital of Atlanta. In 2008, Dr. Kugathasanand his colleagues from six other centers successfullyinitiated a pilot study to demonstrate their capabilityto execute on all fronts, with a biobank, a data center,and a DNA core laboratory ready for service. The col-lection and storage of biological samples from allover the country are some of the core functions of thestudy. A centralized Biospecimen Repository Centeris being set up at Emory Children’s Center.
The Pediatric Network will enroll eleven hundred patients and identify the risk factors from the biological materials collected in this innovative clinical research study.
“Ultimately, our goal is to prevent IBD in the nextgeneration. In the short term, we want more effectivetreatment and total management from day one.
R. Balfour Sartor, M.D., CCFA’s Chief Medical Advisor
Subra Kugathasan, M.D., Chair of Pediatric Network:“For the first time, we are collecting (and banking forfuture use) biological samples from large prospectivepatient populations at the time of diagnosis, beforeany therapies are started. We will bank DNA, bloodserum, stool, and tissue biopsies for future IBD research over the next 20 to 30 years. The overall intention is to provide access to this valuable dataand biological materials, so that discoveries andbreakthroughs can occur. I believe there is no otherbiobank pertaining to IBD like this in the world, noteven at the National Institutes of Health.”
From left to right: R. Balfour Sartor, M.D., Rob Knight, Ph.D., Lloyd Mayer, M.D., Jeffrey I. Gordon, M.D., and Bruce E. Sands, M.D.
IBD Support, Education, andAdvocacy Investments
Research Report
9
CCFA is investing in remaining the leadingsource of unbiased, accurate, and current information related to IBD for patients, families and health professionals.
• The CCFA Information Resource Center(IRC), in its second year, assisted 13,000patients, families, and professionals anddistributed over 110,000 pieces of litera-ture. The IRC staff consists of master’s levelInformation Specialists, a coordinator, andmanager of the IRC and public education.The Center responds to 1,250 patient inquiries per month.
• Our community Web site, www.ccfacommu-nity.org, has had more than 356,000 visitorssince its inception in February 2008. Morethan 6,000 people have registered at thesite. Surveys indicate that the site is visitedweekly by many patients who participate ininteractive forums. The Foundation will beenlarging this feature in 2009.
• The IRC offered two patient education teleconferences in 2008 reaching 4,186participants within the USA, supported by corporate funding. This activity is beingexpanded in 2009.
• The Foundation chapters served about4,000 patients per quarter in 2008 with educational and support programs. We de-veloped a program-in-a-box for launch in2009 to increase our reach to underservedcommunities.
• Camp Oasis steadily increases enrollmentfor kids with IBD who can benefit from special summer camp experience. In 2008we had 1,083 campers, compared to 947 in2007.
• Professional education has seen an increasein membership and attendance at local andnational meetings. Attendance at 13 pro-fessional education meetings held by ourchapters grew to 548 physicians andnurses in 2008.
• Our visiting IBD Fellow Program has shapedthe career choices of many IBD specialists.In 2008, twelve fellows completed their ro-tations within specialized IBD departmentsand five have indicated an interest to spe-cialize in IBD as a result of their experience.
• CCFA’s “Advances in IBD 2008” conferenceattracted 1,031 physicians and nurses, anincrease from 805 in 2007. Attendance bynurses doubled with the increased nursingprogramming offered.
• Thanks to a proactive advocacy program,federal support for IBD research at the NIHand CDC continued at $80 million, a 25%increase in a four-year period when globalresearch funding remained relatively flat.The NIDDK is continuing its support of theInflammatory Bowel Disease Genetics Consortium in light of its great success.
• CCFA’s recent annual “Day on the Hill” conference ushered in the introduction ofthe IBD Research and Awareness Act, whileCCFA members met with over 100 legislatorsfrom local districts to obtain large biparti-san sponsorship.
Research AwardsA core function of CCFA’s operation is the solicitation and peer review of grant appli-cations from scientists around the world. In recent years, our process has involved an exhaustive peer review of over 250 proposals per fiscal year. The selection andtraining of reviewers and grant criteria are dynamic and reflect the evolution of scienceand health care.
CCFA grants are awarded based on merit and best fit for the research strategies es-tablished by the Foundation. CCFA maintains a strategic plan and periodically reviewsthe field of IBD to target unmet needs. Our “Challenges in Inflammatory Bowel Diseases” document reflects a multidisciplinary review of the field and is the founda-tion for advances in the scientific understanding and standard of care of IBD.
Research Awards
112008 Research Award Allocations
In 2008, generous donors made it possible to moveahead on crucial research priorities and initiatives,such as the Human Gut Microbiome, the Clinical Alliance, including the Pediatric Research Network,DNA Cell Line Bank, and requests for proposals to identify surrogate markers for IBD.
Highlights of funded research included:
• The development of the Pediatric Network, a majorstep toward the objective of managing pediatricdisease effectively from day one, through the RiskStratification Initiative.
• Bone development and growth research for childrendiagnosed with Crohn’s disease, a crucial priorityfor our youngest patients.
• Investigation of colonic dysplasia and the develop-ment of colon cancer, as well as surrogate markersfor IBD. This includes the search for biological signsthat will identify individuals at a higher risk of de-veloping the disease, pinpoint correct diagnosis, andpredict how the disease will develop over time.
• A prospective study of pregnancy and neonatal out-comes through the CCFA Clinical Alliance to furtherthe goal of improving maternal and infant health.The Clinical Alliance comprises hospital and com-munity health centers from all over the country thatcooperate to bring IBD patients into clinically signif-icant studies of Crohn’s and colitis. Their work hasthe power to transform the day-to-day care of patients.It also provides infrastructure for evaluating thecures of the future.
• CCFA’s largest grant in its history, the CCFA HumanGut Microbiome Initiative. As described in this report, the tools and information resulting from anunprecedented probe of gut microbiota will changethe course of research into these diseases and mayprovide new options for disease management.
CCFA places high value on the continuity of researchby nurturing the next generation of investigators in the field of IBD. The following grant programs arevital for this strategy:
Senior Grants Program These grants are awarded to experienced scientistsfor projects conducted at hospitals, universities, andresearch laboratories around the world.
Research Training Awards ProgramsCCFA offers these awards to stimulate careers in independent investigation of IBD. Candidates mustbe employed by institutions engaged in healthcareand health-related research within the USA and its possessions.
Career Development AwardCandidates for these awards must have five to tenyears of post-doctoral experience, including twoyears of relevant research experience. The researchproject must be in the field of IBD.
Research Fellowship AwardsCandidates must have at least two years of post-doctoral experience. The research project must be in the field of IBD.
Student Research Fellowship AwardsCandidates are undergraduate, medical, or graduatestudents at accredited institutions within the UnitedStates. They conduct full-time research for a minimumof ten weeks with a mentor investigating a subjectrelevant to IBD.
A Personalized Opportunity to Make a Difference
CCFA donors of significant gifts have the opportunityto direct their donation to specific studies through a naming opportunity. The CCFA Annual Report listsnames of the individual donors to the CCFA ResearchProgram. Donors share in the excitement of meetingthe researchers, touring their laboratories, and receiving annual progress reports.
If you are interested in participating, you may contactthe CCFA National Development Department at 800-932-2423, or speak with your local CCFA Chapter.
Grant Opportunities for Researchers
If your field of research applies to IBD, you may applyfor a research grant. Call CCFA’s Research and Scien-tific Department at 800-932-2423, or visit our Website at www.ccfaprofessionals.org.
MICROBIOME Jay and Ann DavisRichard DavisDaniel and Ellen CrownLester and Renee CrownHoward and June EsbinGreenspun Family FoundationArthur and Jayn MarshallCari MarshallTodd MarshallSusan MolaskyNafees and Shamin NagyThe Honorable and Mrs. Ron Parraguirre
Jeffrey I. Gordon, M.D.Washington University School of Medicine, St. Louis, MOCCFA Human Gut Microbiome Initiative
Rob Knight, Ph.D.University of Colorado at BoulderCCFA Human Gut Microbiome Initiative
RESEARCH INITIATIVES
CLINICAL RESEARCH ALLIANCE
Robert S. Sandler, M.D.University of North Carolina at Chapel Hill, Chapel Hill, NCClinical Research Alliance: Data Management Center
Bruce E. Sands, M.D.Massachusetts General Hospital, Boston, MAClinical Research Alliance: Administrative
PEDIATRIC NETWORK Edward M. BernsteinLawrence FinkelsteinMr. and Mrs. Melvin FinkelsteinGordon and Regina FordSteven and Susan GringauzSeymour and Carol Levin Foundation
Subra Kugathasan, M.D.Emory Children’s Center, Atlanta, GARisk stratification and identification of immunogenetic markers ofcomplicated disease course in pediatric Crohn’s disease
Karis LovettClinipace, Research Triangle Park, NCCCFA Pediatrics Data Platform
EPIDEMIOLOGY INITIATIVE
Lisa Herrinton, Ph.D.Kaiser Foundation Research Institute, Oakland, CAPractice variation in management of inflammatory bowel diseases(Funding through the CDC)
Bruce E. Sands, M.D.Massachusetts General Hospital, Boston, MAOSCCAR: A novel, population-based prospective inception cohort of inflammatory bowel diseases (Funding through the CDC)
PEDIATRIC BONE GROWTH AND SKELETAL HEALTH The Litwin and Swarzman Family
Robert N. Cooney, M.D.The Pennsylvania State University, Hershey, PAMechanisms and therapies for growth failure in intestinal inflammation
Lee A. Denson, M.D.Cincinnati Children’s Hospital Medical Center, Cincinnati, OHImmuno-genetics determinants of linear growth in pediatric IBD
Serge Ferrari, M.D.University Hospital of Geneva, Geneva, SwitzerlandSkeletal microstructure and bone fragility in young patients with inflammatory bowel diseases: Novel diagnostic and therapeutic approaches
Laura R. McCabe, Ph.D.Michigan State University, East Lansing, MIMechanisms of IBD suppression of skeletal growth and mineral density
Ian R. Sanderson, M.D.University of London, London, EnglandPharmacokinetic studies of recombinant human insulin-like growthfactor I (rhIGF-I) rhIGF-binding protein-3 complex in children withCrohn’s disease-induced growth retardation
Leanne M. Ward, M.D.Children’s Hospital of Eastern Ontario (CHEO) Research Institute,Ottawa, Ontario, CanadaThe bone mass deficit in pediatric Crohn’s disease: the role of muscle function and cytokines
DYSPLASIA AND CANCER The Ethel Wilson Bowles and Robert Bowles Memorial FundLeon and Toby CoopermanThe Gillman Family: Shaldine, Richard, Sloane, Marc, Andrea,
and ScottMark and Diane Goldman Greater Los Angeles/Orange County Chapter Research AllianceLinda Tallen and David Paul Kane Cancer Educational and
Research Foundation F.M. Kirby FoundationGary and Lanie Sinderbrand
Teresa A. Brentnall, M.D.University of Washington School of Medicine, Seattle, WABiomarkers of colonic dysplasia and cancer in UC patients with PSC
Mary P. Bronner, M.D.The Cleveland Clinic Foundation, Cleveland, OHGenomic instability biomarkers of cancer in Crohn’s disease
Donors who have generously sponsored this research are indicated in bold.
Research Awards
13Lee Goodglick, Ph.D.University of California, Los Angeles, Los Angeles, CAIdentification of early detection biomarkers for colon cancer in ulcerative colitis patients using mass spectroscopy protein profiling
Antonia R. Sepulveda, M.D., Ph.D.University of Pennsylvania School of Medicine, Philadelphia, PAInflammatory bowel disease epigenetic markers
SURROGATE MARKERS The Bruce and Cynthia Sherman Charitable Foundation, Inc.Donald and Mary Jo LenauerJed Manocherian
Dirk Foell, M.D.University Hospital of Muenster, Muenster, GermanyValidation of phagocyte-derived S100A12 as a surrogate marker of intestinal inflammation in inflammatory bowel diseases (IBD)
Kenneth E. Hung, M.D., Ph.D.Tufts-New England Medical Center, Boston, MAMass spectrometry-based discovery of serum Crohn’s disease activity biomarkers
Ellen Li, Ph.D.Washington University School of Medicine, St. Louis, MOMolecular determinants of postoperative recurrence of Crohn’s diseaseDonald and Mary Jo Lenauer
DNA BANK Joseph Drown FoundationF.M. Kirby FoundationPeter and Joan McKeeModell Family FoundationDonald W. Reynolds FoundationAnne and Henry Zarrow FoundationMaxine and Jack Zarrow Family Foundation
Kristin Ardlie, Ph.D.Broad Institute, Cambridge, MAPurchase of matched control samples; plating, distribution, and storage of samples for the DNA and Cell Line Bank
Lorraine H. Toji, Ph.D.Coriell Cell Repositories, Camden, NJEstablishment and maintenance of a DNA and Cell Line Bank
Robert S. Sandler, M.D.University of North Carolina at Chapel Hill, Chapel Hill, NCDNA and Cell Line Bank Data Management Center (formerly entitled“IBD genotyping database project”)
Andrew T. Ippoliti, M.D.Cedars-Sinai IBD Center, Los Angeles, CADNA and Cell Line Bank-Patient Acquisition Center (PAC)
SENIOR RESEARCH AWARDS
Clara Abraham, M.D.Yale University School of Medicine, New Haven, CTLFA-1 and regulatory T cells
Saverio Bellusci, Ph.D.The Saban Research Institute of Children’s Hospital Los Angeles, CAGrowth factors in gut adaptation
Marc Bissonnette, M.D.University of Chicago, Chicago, ILCharacterization of a model of chronic ulcerative colitis in AOM/DSS-treated Hsp722 knock-out mice
Richard S. Blumberg, M.D.Brigham & Women’s Hospital, Boston, MARole of the unfolded protein response in colitis
David Boone, Ph.D.University of Chicago, Chicago, ILThe role of ubiquitin regulation of intestinal epithelial cell function in IBD
Steven R. Brant, M.D.Johns Hopkins University, Baltimore, MDThe Mid-Atlantic African-American IBD Study: Exploring racial disparities
Elke Cario, M.D.University Hospital of Essen, Essen, GermanyCytoprotective role of toll-like receptor 2 in the intestinal epithelium
Shukti Chakravarti, Ph.D.Johns Hopkins University, Baltimore, MDRole of lumican in colitis
Eugene B. Chang, M.D.University of Chicago, Chicago, ILRole of OCTN1 and OCTN2 in maintaining intestinal homeostasis andin the pathogenesis of IBD
Ru Chen, Ph.D.University of Washington School of Medicine, Seattle, WAProtein signatures for ulcerative colitis (UC) and its risk for colorectal cancerNorthwest Chapter Research Alliance
Bobby J. Cherayil, M.D.Massachusetts General Hospital, Charlestown, MAThe role of indoleamine 2.3 dioxygenase (IDO) in intestinal inflammation
Donald A. Cohen, Ph.D.University of Kentucky Medical Center, Lexington, KYProtective role of macrophages in the development of inflammatorybowel diseases
Sean P. Colgan, Ph.D.University of Colorado Health Science Center, Denver, COEpithelial Ecto-5’-nucleotidase (CD73) and IFNa in IBDNortheast Ohio Chapter Research Initiative
Vojo P. Deretic, Ph.D.University of New Mexico, Albuquerque, NMAutophagy in Crohn’s disease
Kenneth Dorshkind, Ph.D.University of California, Los Angeles, Los Angeles, CAIntestinal B cell development and function
Brian G. Feagan, M.D.Robarts Research Institute, London, Ontario, CanadaA phase III randomized, placebo-controlled, double-blind, parallelgroup, multi-center study to evaluate the safety and efficacy of infliximab in combination with methotrexate for the long-termtreatment of Crohn’s disease
Hudson H. Freeze, Ph.D.The Burnham Institute, La Jolla, CAMolecular basis of a novel therapeutic antibody for inflammatorybowel diseases
Andrew T. Gewirtz, Ph.D.Emory University, Atlanta, GATLR5-regulation of innate and adaptive immunity in IBD
Eileen F. Grady, Ph.D.University of California, San Francisco, San Francisco, CADysregulation of receptor signaling leads to intestinal inflammation
George H. Greeley, Jr., Ph.D.University of Texas Medical Branch, Galveston, TXRole of apelin in inflammatory bowel diseases
Hans Herfarth, M.D., Ph.D.University of North Carolina at Chapel Hill, Chapel Hill, NCDouble-blind, placebo-controlled, randomized, multi-center, pilotstudy on the safety and efficacy of ciprofloxacin for prophylactic prevention of postoperative endoscopic recurrence in Crohn’s disease patients
Harvey R. Herschman, Ph.D.University of California, Los Angeles, Los Angeles, CAThe role of inflammatory and stromal cell COX-2 production in ulcerative colitis and colitis-associated colon cancerBarbara and Fred Miller
Peter D. Higgins, M.D., Ph.D.University of Michigan, Ann Arbor, MIA novel, valid disease activity index for clinical researchin ulcerative colitis
I-Cheng Ho, M.D., Ph.D.Brigham & Women’s Hospital, Boston, MAEts-1 as a therapeutic target of Crohn’s disease
Lora V. Hooper, Ph.D.University of Texas Southwestern Medical Center at Dallas, Dallas, TXInteractions between commensal bacteria and yS intraepitheliallymphocytes in mucosal injury
Christian Jobin, Ph.D.University of North Carolina, Chapel Hill, NCRole of bacteria in colitis-associated colon cancerMichael Libretti Memorial Research Fund
Chang H. Kim, Ph.D.Purdue University, West Lafayette, INMechanisms of immune cell trafficking in inflammatory bowel diseases
Jan-Michael A. Klapproth, M.D.Emory University, Atlanta, GABacterial TNF-alpha inducing effector proteins
Stephen M. Krane, M.D.Massachusetts General Hospital, Charlestown, MARoles of collagenolysis and collagenolytic matrix metallopro-teinases in the experimental inflammatory bowel diseases that accompany mucosal injury in mice
Juan J. Lafaille, Ph.D.New York University School of Medicine, New York, NYImproving the efficacy of regulatory T cells in inflammatory bowel diseasesThe Pamela Darnell Research Fund
Wayne I. Lencer, M.D.The Children’s Hospital of Boston, Boston, MAFcRn-dependent transepithelial processing of IgG-opsinized microbes and microbial products in the inflammatory response
Hongmin Li, Ph.D.Health Research Inc./NYSDOH, Albany, NYStructure and host recognition of the Crohn’s disease-associatedprotein PfiT
Pauline K. Lund, Ph.D.University of North Carolina, Chapel Hill, NCRole of suppressor of cytokine signaling 3 in epithelial repair and tumorgenesis during injury and inflammationGet Your Guts in Gear
Averil Ma, M.D.University of California, San Francisco, San Francisco, CANovel regulation of T cell mediated colitis by a ubiquitin modifying enzyme
Lillian Maggio-Price, Ph.D.University of Washington School of Medicine, Seattle, WAInflammation and TGFB dysregulation in the evolution of colon cancer
Uma Mahadevan, M.D.University of California, San Francisco, San Francisco, CAA multicenter national prospective study of pregnancy and neonataloutcomes in women with inflammatory bowel diseases
Research Awards
15Lloyd Mayer, M.D.Mount Sinai School of Medicine, New York, NYThe role of carcinoembryonic antigen in mucosal immunity
Mark Mooseker, Ph.D.Yale University School of Medicine, New Haven, CTThe enterocyte actin cytoskeleton and maintaining the intestinal mucosal barrier
Yuriko Mori, Ph.D.Johns Hopkins University, Baltimore, MDA genome-wide search for novel methylation targets in inflammatorybowel diseases-associated colon cancer
Bruce Paster, Ph.D.The Forsyth Institute, Boston, MABacterial associations of the gastrointestinal tracts of subjects withCrohn’s disease
Marcus Peter, Ph.D.University of Chicago, Chicago, ILA novel role of the “death receptor” Fas as a protector from colitis
Scott E. Plevy, M.D.University of North Carolina at Chapel Hill, Chapel Hill, NCCarbon monoxide, cigarette smoking, and IBD
D. Brent Polk, M.D.Vanderbilt University School of Medicine, Nashville, TNErbB-4 regulations of intestinal inflammatory wound healing and repair
Lynn Puddington, Ph.D.University of Connecticut Health Center, Farmington, CTAntigen acquired from breast milk induces mucosal regulatoryT cells
Eyal Raz, M.D.UCSD-The Regents of the University of California, La Jolla, CAPRR-activated dendritic cells regulate experimental colitis
Maria Rescigno, Ph.D.European Institute of Oncology, Milan, Italy Study of the defects of TSLP expression in Crohn’s disease patientnew therapeutic strategies
John D. Rioux, Ph.D.Montreal Heart Institute, Montreal, Quebec, CanadaA biological pathway approach to understanding IBDLouisiana/Mississippi Chapter Research Alliance
Bruce E. Sands, M.D.Massachusetts General Hospital, Boston, MAResponse to infliximab for active ulcerative colitis: A multi-center,prospective assessment of predictors of response to infliximab
R. Balfour Sartor, M.D.University of North Carolina at Chapel Hill, Chapel Hill, NCDietary metal-bacterial interactions in immune-mediated intestinal inflammationLong Island Chapter Research Alliance
Suzana D. Savkovic, Ph.D.Evanston Northwestern Healthcare Research Institute, Evanston, ILCross-communication between intestinal inflammation and tumorigenesis: The role of Foxo3a in intestinal inflammation
Cynthia L. Sears, M.D.Johns Hopkins University, Baltimore, MDDefining microbial and immune contributors to pediatric IBDWestern Pennsylvania/West Virginia Chapter Research Initiative
Mark H. Siegelman, M.D., Ph.D.University of Texas Southwestern Medical Center at Dallas, Dallas, TXAdhesion markers for T cell regulatory activity in inflammatorybowel diseasesThe William Stamps Farish Fund
Shanthi V. Sitaraman, M.D., Ph.D.Emory University, Atlanta, GAProhibitin: A novel antioxidant moleculeElvin and Janet Price
Thomas C. Smyrk, M.D.Mayo Clinic and Foundation, Rochester, MNInvestigating the methylation status of genes of interest in UC-CRC:Testing for field effect in non-dysplastic adjacent tissue from colectomy samples to identify diagnostic markers for use in surveillance biopsies
Thaddeus S. Stappenbeck, M.D., Ph.D.Washington University School of Medicine, St. Louis, MOCellular and molecular factors of the epithelial stem cell niche thatthe colonic mucosal injury response
Manjunath N. Swamy, M.D.Texas Tech University Health Sciences Center, El Paso, TXRole of CD27-CD70 costimulatory pathway in inflammatory bowel diseases
Eva Szigethy, M.D., Ph.D.University of Pittsburgh, Pittsburgh, PAImproving quality of life using cognitive behavioral therapy in depressed youth with inflammatory bowel diseases
Cornelis P. Terhorst, Ph.D.Beth Israel Deaconess Medical Center, Boston, MAStudy of CD84 induced innate and adaptive immune responses in experimental colitis
Michael J. Wannemuehler, Ph.D.Iowa State University, Ames, IAMicrobial perturbation of mucosal homeostasis: Predispositionto colitis
Ifor Williams, M.D., Ph.D.Emory University, Atlanta, GARegulation of organized intestinal lymphoid tissues by trance/rankl
Mei X. Wu, M.D., Ph.D.Massachusetts General Hospital, Boston, MASmad phosphatase’s regulation and function in T cells
Lijun Xia, M.D., Ph.D.Oklahoma Medical Research Foundation, Oklahoma City, OKRole of intestinal O-glycans in the pathogenesis of ulcerative colitis
Huabao Xiong, M.D., Ph.D.Mount Sinai School of Medicine, New York, NYThe essential role of IFN consensus sequence-binding protein inthe development of colitis
Fang Yan, M.D., Ph.D.Vanderbilt University School of Medicine, Nashville, TNRegulatory effects of probiotic-derived soluble proteins on colitis
Guang-Yu Yang, M.D., Ph.D.Northwestern University, Chicago, ILInositol and chemoprevention of ulcerative colitis-induced carcinogenesis
Wei-Ping Zeng, Ph.D.University of Rochester School of Medicine, Rochester, NYRole of Foxp3 in inflammatory bowel diseases
CAREER DEVELOPMENT AWARDS
Laetitia Charrier, Ph.D.University of Pennsylvania School of Medicine, Philadelphia, PARoles of ADAM-15 in inflammatory bowel diseases
Matthew A. Ciorba, M.D.Washington University School of Medicine, St. Louis, MOIndoleamine 2,3 dioxygenase (IDO) in intestinal inflammation:Assessment of IDO induction agents to abrogate colitis and correlation of IDO activity to human inflammatory bowel diseases
Beckley K. Davis, Ph.D.University of North Carolina at Chapel Hill, Chapel Hill, NCNucleotide binding in NLR-Mediated inflammation and carcinogenesis
Timothy L. Denning, Ph.D.Emory University, Atlanta, GAThe role of antigen-presenting cells in modulating intestinal immune responses
Raja Fayad, M.D.University of Illinois at Chicago, Chicago, ILRole of adipokines in inflammatory bowel diseases
Masayuki Fukata, M.D., Ph.D.University of Miami, Miami, FLThe role of TLR4 signaling in colitis-associated cancer
Neera Gupta, M.D.University of California, San Francisco, San Francisco, CAGender differences in growth in pediatric patients with Crohn’s disease
Neera Gupta, M.D.University of California, San Francisco, San Francisco, CAGender differences in growth in pediatric patients with Crohn’s diseaseCCFA’S Co-Sponsored Young Investigator Award Children’s Digestive Health and Nutrition Foundation (Co-Sponsored Award through NASPGHAN)
Xiaonan Han, Ph.D.Cincinnati Children’s Hospital Medical Center, Cincinnati, OHCharacterization of STAT5b as a novel therapeutic target in Crohn’s disease
Simon P. Hogan, Ph.D.Cincinnati Children’s Hospital Medical Center, Cincinnati, OHEosinophils and pediatric inflammatory bowel diseases
Eric Houpt, M.D.University of Virginia/Digestive Health Ctr, Charlottesville, VAControl of innate intestinal inflammation in mice
Li-Chung Hsu, Ph.D.University of California, San Francisco, La Jolla, CAThe molecular mechanism of NOD2 in the pathogenesis of Crohn’s Disease
Andrei I. Ivanov, Ph.D.University of Rochester School of Medicine, Rochester, NYThe role of endocytic recycling of junctional proteins during mucosal restitution IBD
Matam V. Kumar, Ph.D.Emory University, Atlanta, GARole of adaptive immunity in the development of spontaneous colitis in toll-like receptor-5 (TLR-5) deficient mice
Sarkis K. Mazmanian, Ph.D.California Institute of Technology, Pasadena, CAThe molecular mechanism of symbiotic commensal protectionagainst colitis
Christine McDonald, Ph.D.The Cleveland Clinic Foundation, Cleveland, OHMolecular mechanisms of activation and regulation of the Crohn’sdisease associated protein NOD2
J. Rodrigo Mora, M.D., Ph.D.Massachusetts General Hospital, Boston, MAMicroenvironmental programming of intestinal dendritic cells to imprint gut-tropism in lymphocytes
Masako Murai, M.D., Ph.D.La Jolla Institute for Allergy & Immunology, La Jolla, CAPrevention of colitis mediated by IL-10 and regulatory T cells
Brian M. Necela, Ph.D.Mayo Clinic Jacksonville, Jacksonville, FLCellular and molecular targets essential for the protection againstthe development of ulcerative colitis
Research Awards
17Darrell B. O’Quinn, Ph.D.University of Alabama at Birmingham, Birmingham, ALFunctional roles of IL-6 and IL-23 in regulating Th17-mediated colitis modelsAlabama/Northwest Florida Chapter Research AllianceLance Robert McLendon Memorial Tournament
Helen Pappa, M.D.The Children’s Hospital of Boston, Boston, MAOptimization of vitamin D status and its impact on bone health and disease outcomes in young patients with inflammatory bowel diseases
Steven Polyak, M.D.University of Florida, Gainesville, FLTargeted gene delivery to the intestinal epithelium for the study and treatment of colitisFlorida Chapter Research AllianceThe Retirement Research Foundation
Seema Saksena, Ph.D.University of Illinois at Chicago, Chicago, ILRegulation of intestinal chloride absorption by neuropeptide Y
Corey A. Siegel, M.D.Dartmouth Medical School, Lebanon, NHRisk communication in Crohn’s disease
Kris A. Steinbrecher, Ph.D.Cincinnati Children’s Hospital Medical Center, Cincinnati, OHRole of NF-kB/GSK-3-mediated gene expression in initiation of inflammatory bowel diseases
Michael C. Stephens, M.D.Medical College of Wisconsin, Milwaukee, WIABC transporter pharmacogenetics impact on thiopurine therapyCCFA’S Co-Sponsored Young Investigator Award Children’s Digestive Health and Nutrition Foundation (Co-Sponsored Award through NASPGHAN)
Fernando Velayos, M.D.University of California, San Francisco, San Francisco, CA5-ASA use and risk of colorectal dysplasia and cancer among ulcerative colitis patients
You-Qing Zhang, Ph.D.University of California, San Diego, La Jolla, CAInvolvement of activin signaling in the pathogenesis of inflammatorybowel diseases
Zili Zhang, M.D., Ph.D.Oregon Health and Science University, Portland, OROXO40 and th17 cell activation in inflammatory bowel diseases
RESEARCH FELLOWSHIP AWARDS
Abraham L. Brass, M.D., Ph.D.Massachusetts General Hospital, Boston, MAAn RNAi strategy for the identification of factors required for TNF-ainduced apoptosis
Eric L. Campbell, Ph.D.University of Colorado Health Science Center, Denver, COMechanisms of intestinal inflammation resolution via lipid mediatorsRocky Mountain Chapter Research Alliance
Bindu P. Chandrasekharan, Ph.D.Emory University, Atlanta, GANeuropeptide Y and neurogenic inflammation in inflammatorybowel diseases
Xinhua Chen, Ph.D.Beth Israel Deaconess Medical Center, Boston, MAMechanisms of protective role of saccharomyces boulardii in intestinal inflammation and neoplasiaJames D. Ireland, IV
Alex Chung Kyu Chin, Ph.D.Emory University, Atlanta, GAEffect of neutrophil transmigration and epithelial pathophysiologyin inflammatory bowel diseases
Guillaume Dalmasso, Ph.D.Emory University, Atlanta, GARole of the anti-inflammatory tripeptide KPV in IBD
Sara Dann, Ph.D.University of Texas Medical Branch, Galveston, TXNovel strategy of probiotic intervention in intestinal inflammation
Lopamudra Das, Ph.D.Case Western Reserve University, Cleveland, OHMechanism of TGF-B-Mediated suppression of T cell receptor signal transduction in IBD
Porfirio N. Dominguez, Ph.D.Emory University, Atlanta, GARole of desmosomal cadherins in the regulation of the intestinal epithelial barrier in IBD
Benjamin Faustin, Ph.D.The Burnham Institute, La Jolla, CABiochemical mechanisms regulating NAC function in IL-1b processing
Pallavi Garg, Ph.D.Emory University, Atlanta, GACharacterization of metalloproteinase-2 in inflammatory bowel diseases
Mordechay Gerlic, Ph.D.The Burnham Institute, La Jolla, CAMechanisms of NALP1 inflammasome regulation by Bcl-2 and Bcl-XL
Ana Belen Blazquez Gonzalez, Ph.D.Mount Sinai School of Medicine, New York, NYThe role of thymic stromal lymphopoietin (TSLP) in the homeostatisof mucosal immunity
Helen Goodridge, Ph.D.Cedars-Sinai IBD Center, Los Angeles, CAThe role of NFAT in shaping innate inflammatory responses
Sergei Grivennikov, Ph.D.UCSD-The Regents of the University of California, La Jolla, CARole of cytokines and adaptive immunity in chronic colon inflammation and tumorigenesis
Matija Hedl, Ph.D.Yale University School of Medicine, New Haven, CTNOD2-mediated self-tolerance and cross-tolerance to toll-like receptors 2 and 4
Shien Hu, M.D., Ph.D.University of Chicago, Chicago, ILPost-transcriptional regulation of heat shock proteins by pro-inflammatory cytokines: Contribution to IBD pathogenesis
Ivaylo Ivanov, Ph.D.New York University School of Medicine, New York, NYRole of RORyt+ cells and cryptopatches in the pathogenesis of IBDand mucosal immunity
Rheinallt M. Jones, Ph.D. Emory University, Atlanta, GAA novel genetic system to study host bacterial interactionsDr. and Mrs. James F. Rooney
Iordanis Karagiannidis, Ph.D.University of California, Los Angeles, Los Angeles, CASP-mediated involvement of mesenteric fat tissue in the developmentof inflammatory bowel diseases
Hon Wai Koon, Ph.D.University of California, Los Angeles, Los Angeles, CAMechanisms of the healing effects of substance P in intestinal inflammation
Narendra Kumar, Ph.D.Texas A&M Research Foundation, Kingsville, TXRole of JAK3-villin interaction in the restitution of intestinal epithelial cells
Courtney C. Kurtz, Ph.D.University of Virginia/Digestive Health Ctr, Charlottesville, VAThe role of A2AAR in T cell mediated colitis
Jessica J. Lee, M.D.The Children’s Hospital of Boston, Boston, MAGenetics of growth failure in pediatric inflammatory bowel diseasesRonald A. Krancer Research Award
Katsuyoshi Matsuoka, M.D., Ph.D.University of North Carolina at Chapel Hill, Chapel Hill, NCEndogenous danger signals in IBD
Francoise Meylan, Ph.D.National Institutes of Health, NIAMS, Bethesda, MDRole of TL1A-DR3 TNF-family interactions in inflammatory bowel diseases
Aylwin Ng, Ph.D.Massachusetts General Hospital, Boston, MAElucidating functional network modules and novel effectors in TLR/NOD-LPP-mediated signal transduction relevant to IBD pathogenesisusing integrative systems and bioinformatics approaches
Marie Anne O’Donnell, Ph.D.Mount Sinai School of Medicine, New York, NYRegulation of TNF-induced NF-Kb activation and cell death by ubiquitination of RIP
Shigeru Oshima, M.D., Ph.D.University of California, San Francisco, San Francisco, CARegulation of ubiquitylation and T cell mediated colitis
Dmitry V. Ostanin, Ph.D.Louisiana State University Health Sciences Center, Shreveport, LARoles of T-cell-associated Alpha4 integrins in the pathogenesis of chronic colitisLouisiana/Mississippi Chapter Research Initiative
Yunji Park, Ph.D.La Jolla Institute for Allergy & Immunology, La Jolla, CARole of mucosal dendritic cells in the immune regulation and pathogenesis of gut inflammation
Iryna V. Pinchuk, Ph.D.University of Texas Medical Branch, Galveston, TXColonic myofibroblasts-T cells interactions: Implication in immunopathogenesis of ulcerative colitis
Ki-Jong Rhee, Ph.D.Johns Hopkins University, Baltimore, MDMurine model of colonic inflammation by enterotoxigenic bacteroides fragilis
Javier R. Ros, Ph.D.Beth Israel Deaconess Medical Center, Boston, MARole of the cell surface receptor SLAMF6 (Ly108) in experimental colitisGet Your Guts in Gear
Nikolayevich Samarin, Ph.D.Emory University, Atlanta, GARegulation of epithelial apical junctional complex in IBD
Le Shen, M.D., Ph.D.University of Chicago, Chicago, ILEpithelial tight junction regulation and immune activation in IBDMichael McAteer Memorial Research Fund
Ken Sugimoto, M.D., Ph.D.Massachusetts General Hospital, Boston, MARole of interleukin-22 in epithelial cell function and colitis
Michael Verzi, Ph.D.Dana-Farber Cancer Institute, Boston, MAUnderstanding intestinal epithelial cell function by defining the Cdx2
Research Awards
19Flavia A. Wald, Ph.D.University of Miami, Miami, FLBiogenesis of the apical ezrin scaffold and diarrheal disorders
Caihong Wang, Ph.D.Washington University School of Medicine, St. Louis, MOThe role of a4 integrins in isolated lymphoid follicles formation
Yutao Yan, Ph.D.Emory University, Atlanta, GARole of integrin-associated protein CD98 in intestinal permeability
Sebastian Zeissig, M.D.Brigham & Women’s Hospital, Boston, MACharacterization of natural killer T cells in the murine intestine
David Alexander Ziring, M.D.University of California, Los Angeles, Los Angeles, CAManipulation of immunoregulatory B cells in colitis
STUDENT RESEARCH FELLOWSHIP AWARDS
Balaji AyyarCase Western Reserve University, Cleveland, OHRho-GTPase regulation of control and IBD LPT migration throughcontrol and IBD extracellular matrixGet Your Guts in Gear
Swathi EluriJohns Hopkins University, Baltimore, MDCan differential expression of SLAP and betacellulin genes identifiedby gene array be used for predictive biomarkers for IBD-associatedcolon cancerThe George Kitzes Student Research Grant
Yoon-Jung Mickey HyunWashington University School of Medicine, St. Louis, MOIndoleamine 2,3 dioxygenase in a chronic model of colitis
Aaron Kyle JenkinsEmory University, Atlanta, GATranscriptional inhibition of prohibitin by TNF-alphaGet Your Guts in Gear
Allyson McLoedMassachusetts General Hospital, Boston, MAInvestigation of the effect of helminth on epithelial barrier functionGet Your Guts in Gear
Amy PetzelUniversity of Chicago, Chicago, ILThe grading of inflammation in patients with ulcerative colitis by symptoms, serology, histology, optical coherence tomography, fecal marker, and endoscopyGet Your Guts in Gear
Steven RussoUniversity of North Carolina at Chapel Hill, Chapel Hill, NCInnate immune defects and IBD in P13 kinase in p110δ mutantGet Your Guts in Gear
Daniel E. SchlossMassachusetts General Hospital, Charlestown, MAThe role of cystic fibrosis trans-membrane receptor in intestinal inflammationGet Your Guts in Gear
Scott M. TannerUniversity of Alabama at Birmingham, Birmingham, ALEffects of estrogen on regulatory T cell function in a mouse model of colitis
Charles VainderEvanston Northwestern Research Institute, Evanston, ILRegulation of tumor suppressor Foxo3a by lipopolysaccharide in intestinal epithelial cells and its contribution in IL-8 expressionIn honor of Christopher D. Maier, Sr.
Tomas VanagunasNorthwestern University, Chicago, ILExamination of beta catenin signaling in IBD
Kaitlin WantaNorthwestern University, Chicago, ILGrowth factor induced stem cell activation in colitisWarren and Roberta Sirzyk and Family
Randolph D. WinnegarNorthwestern University, Chicago, ILThe role of inositol in colitis induced cancer
WORKSHOPS/CONFERENCES
Mark H. Epstein, Sc.D.Society for Mucosal Immunology, Bethesda, MDAntigen recognition at mucosal surfaces: Implications for allergic,inflammatory and immunologic diseases. Satellite symposium for FOCIS 2008 meeting
Peter B. Ernst, Ph.D.University of Virginia, Charlottesville, VAMicrobes and mucosal immunity–2008
Claudio Fiocchi, M.D.The Cleveland Clinic Foundation, Cleveland, OHSecond International Symposium on pediatric IBD
The Crohn’s & Colitis Foundation of America (CCFA) achieved revenue of $42.9 millionduring the fiscal year ended August 31, 2008. Our generous and committed donorsmade it possible to reach new goals even as the economic headwinds were gainingforce. We acknowledge all of those who kept the Foundation on its mission course,allowing us to provide research, education, and support services of the highest quality.
In 2008, we allocated more than $34.1 million to mission-critical programs. Morethan 79.3 cents of every dollar spent by CCFA went to research, education, and patient support. As always, our dedication to careful stewardship met the higheststandards of organizations that monitor charities. CCFA again earned an “A” ratingfrom the American Institute of Philanthropy (www.charitywatch.org) and met the 20Standards of Accountability of the Better Business Bureau’s Wise Giving Alliance.
I welcome your inquiries concerning CCFA’s financial results. For more information,please contact the Foundation’s National Headquarters.
Louis PlungTreasurer
Report from the Treasurer
Financial Statements
Financial Statem
ents
21
Grant Thornton LLPUS member firm of Grant Thornton International, Ltd.
Report of Independent Certified Public Accountants
National Board of TrusteesCrohn’s & Colitis Foundation of America, Inc.
We have audited the accompanying statements of financial positionof the Crohn’s & Colitis Foundation of America, Inc. (the Foundation)as of August 31, 2008 and 2007, and the related statements of ac-tivities, cash flows and functional expenses for the years then ended.These financial statements are the responsibility of the Foundation’smanagement. Our responsibility is to express an opinion on thesefinancial statements based on our audits.
We conducted our audits in accordance with auditing standards gen-erally accepted in the United States of America as established by theAmerican Institute of Certified Public Accountants. Those standardsrequire that we plan and perform the audits to obtain reasonable as-surance about whether the financial statements are free of materialmisstatement. An audit includes consideration of internal controlover financial reporting as a basis for designing audit proceduresthat are appropriate in the circumstances, but not for the purpose ofexpressing an opinion on the effectiveness of the Foundation’s in-ternal control over financial reporting. Accordingly, we express nosuch opinion. An audit also includes examining, on a test basis, ev-idence supporting the amounts and disclosures in the financialstatements, assessing the accounting principles used and signifi-
ASSETSCash and cash equivalents Pledges receivable, netPrepaid expenses and other assets InvestmentsCharitable gift annuities Charitable remainder trustsFurniture, equipment, and leasehold improvements, net Total assets
LIABILITIES AND NET ASSETSAccounts payable and accrued expenses Research grants payable Gift annuity liabilityDeferred revenue and refundable advancesDeferred rent Capitalized lease obligationTotal liabilities
Net assetsUnrestricted Temporarily restricted
Total net assets Total liabilities and net assets
$3,521,941 5,483,929
784,24913,908,671
287,727 341,872
1,292,861 $25,621,250
$1,575,746 10,409,191
288,172
1,434,336 178,347 89,091
13,914,883
5,226,115 6,480,252
11,706,367$25,621,250
STATEMENTS OF FINANCIAL POSITIONAugust 31,
The accompanying notes are an integral part of these statements.
$4,045,507 5,195,731 1,154,267
11,126,530 295,422 311,920
1,028,237 $23,157,614
$1,679,639 8,641,721
243,798
795,020 218,491
37,121 11,615,790
6,120,785 5,421,039
11,541,824 $23,157,614
2008 2007
Cash flows from operating activities Change in net assets Adjustments to reconcile change in net assets to net cash and cash equivalents used in operating activities
Depreciation and amortization Deferred rent Net realized and unrealized loss (gain) on investments Charitable remainder trustsProvisions for doubtful accountsChanges in operating assets and liabilities
Pledges receivablePrepaid expenses and other assets Accounts payable and accrued expenses Research grants payable Deferred revenue and refundable advances Charitable gift annuities
Net cash and cash equivalents (used in)operating activities Cash flows from investing activities
Purchases of investmentsProceeds from sale of investmentsPurchases of furniture and equipmentNet cash and cash equivalents providedby investing activities
Cash flows from financing activities Borrowings under capital leaseRepayment of capital lease obligation
Net cash and cash equivalents (used in) provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents,beginning of yearCash and cash equivalents, end of year
$(164,543)
433,281 40,144
238,507 29,95261,752
226,446(370,018)
103,893(1,767,470)
(639,316)(27,644)
(1,835,016)
(13,249,426)15,828,635
(168,657)
2,410,552
–(51,970)
(51,970)
523,566
3,521,941$4,045,507
STATEMENTS OF CASH FLOWSFor the the year ended August 31,
The accompanying notes are an integral part of these statements.
cant estimates made by management, as well as evaluating the overallfinancial statement presentation. We believe that our audits providea reasonable basis for our opinion.
In our opinion, the financial statements referred to above presentfairly, in all material respects, the financial position of the Crohn’s &Colitis Foundation of America, Inc. as of August 31, 2008 and 2007,and the changes in its net assets and cash flows for the years thenended in conformity with accounting principles generally accepted inthe United States of America.
Philadelphia, Pennsylvania April 15, 2009
Grant Thornton LLP
$1,010,721
427,023 36,784
(759,530) (22,831)145,000
(3,000,258)588,618
(560,397)456,411
307,645(23,355)
(1,394,169)
(26,379,607)28,574,564
(488,373)
1,706,584
148,485(59,394)
89,091
401,506
3,120,435$3,521,941
2008 2007
Contributions, other income and reclassificationsContributionsContributions from individuals, foundations and corporationsContributed airtime
Special events revenue Less: direct benefit to donor costsNet special events revenue
Total contributions
Other income (loss)Interest and dividend incomeNet realized and unrealized gain (loss) on investmentsFederal grant revenueOther
Total other income
Total contributions and other income
Net assets released from restrictions
Total contributions, other income and reclassifications
ExpensesProgram servicesResearchHealth professional education and public information
Total program services
Supporting servicesManagement and generalFund-raising
Total supporting services
Total expenses
Change in net assets
Net assets, beginning of year
Net assets, end of year
$20,127,2081,690,983
14,525,689 (4,505,736)10,019,953
31,838,144
168,193 (238,507)
509,064 95,168
533,918
32,372,062
11,537,394
43,909,456
14,637,796 19,489,496
34,127,292
4,385,008 4,502,486
8,887,494
43,014,786
894,670
5,226,115
$6,120,785
$10,478,181 –
–––
10,478,181
––––
–
10,478,181
(11,537,394)
(1,059,213)
––
–
––
–
–
(1,059,213)
6,480,252
$5,421,039
$30,605,389 1,690,983
14,525,689 (4,505,736)10,019,953
42,316,325
168,193 (238,507)
509,064 95,168
533,918
42,850,243
–
42,850,243
14,637,796 19,489,496
34,127,292
4,385,008 4,502,486
8,887,494
43,014,786
(164,543)
11,706,367
$11,541,824
Unrestricted
STATEMENTS OF ACTIVITIESFor the year ended August 31,
TemporarilyRestricted Total
The accompanying notes are an integral part of these statements.
$23,152,851 3,965,173
16,506,647 (3,499,651)13,006,996
40,125,020
527,352759,530 369,081 207,531
1,863,494
41,988,514
–
41,988,514
15,460,37418,125,854
33,586,228
4,164,164 3,227,401
7,391,565
40,977,793
1,010,721
10,695,646
$11,706,367
Total
2008 2007
2008 ALLOCATION OF EXPENSE DOLLARS Administration: 10.2%(Management and general)
Fundraising: 10.5%
Program Services: 79.3%
Research grants and awards
Salaries and related expenses
Contract services and feesContributed airtime Publications and related
printed materials Occupancy costs Postage Conferences, conventions
and meetings Telephone and
communications Travel Office supplies
and expensesData processingProvision for doubtful
accountsOther expenses
Total expenses before depreciation
Depreciation and amortization of fixed assets
Total functional expenses
Less:Provision for grant
terminations, refunds, relinquishments and accruals
Direct benefit to donor costs of special events
Total expenses reported by function on the statement of activities
Financial Statem
ents
23
$15,508,006
879,984(30,278)
–
74,765 43,67550,415
398,300
12,128 55,511
19,91419,216
2,03841,944
17,075,618
13,961
17,089,579
(2,451,783)
–
$14,637,796
Research
Program Services Supporting Services
Healthprofessional
educationand public
information Total
Managementand
general Fundraising
Directbenefit to
donor costs Total
$ –
8,747,2231,646,740 1,690,983
1,290,483 819,246 856,891
1,937,476
204,419 535,618
309,726 371,913
38,225 766,782
19,215,725
273,771
19,489,496
–
–
$19,489,496
$15,508,006
9,627,2071,616,4621,690,983
1,365,248862,921 907,306
2,335,776
216,547591,129
329,640 391,129
40,263808,726
36,291,343
287,732
36,579,075
(2,451,783)
–
$34,127,292
$ –
2,200,905357,054
–
349,073 227,245226,611
364,879
55,137 128,551
82,466 99,983
10,603 210,689
4,313,196
71,812
4,385,008
–
–
$4,385,008
$ –
2,259,869366,620
–
358,425 233,333232,682
374,655
56,614131,995
84,675 102,661
10,886 216,334
4,428,749
73,737
4,502,486
–
–
$4,502,486
$ –
– 3,730,179
–
145,954 ––
57,220
––
372,236 –
–200,147
4,505,736
–
4,505,736
–
(4,505,736)
$ –
$15,508,006
14,087,9816,070,315 1,690,983
2,218,7001,323,4991,366,599
3,132,530
328,298 851,675
869,017 593,773
61,752 1,435,896
49,539,024
433,281
49,972,305
(2,451,783)
(4,505,736)
$43,014,786
STATEMENTS OF FUNCTIONAL EXPENSESYear Ended August 31,
The accompanying notes are an integral part of these statements.
2008 2007
Total
$14,444,464
11,295,4685,730,6793,965,173
1,715,5101,232,136
966,244
2,000,587
310,033625,265
583,079 568,471
145,000900,809
44,482,918
427,023
44,909,941
(432,497)
(3,499,651)
$40,977,793
NOTE A. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
1. OrganizationThe Crohn’s & Colitis Foundation of America, Inc. (the Foundation) is a not-for-profit organiza-tion founded in 1965.
The Foundation’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve thequality of life of children and adults affected by these diseases. The Foundation has its head-quarters in New York City (the National Office) and has 41 Chapters (the Chapters) and one vol-unteer affiliate.
2. Basis of PresentationThe financial statements of the Foundation have been prepared in conformity with accountingprinciples generally accepted in the United States of America and in accordance with the pro-visions of Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements ofNot-for-Profit Organizations. SFAS No. 117 requires that net assets and revenues, gains, ex-penses and losses be classified as unrestricted, temporarily restricted or permanently restrictedbased on the existence or absence of donor-imposed restrictions as follows:
Unrestricted - Net assets that are not subject to donor-imposed stipulations. Unrestricted netassets represent resources that are available for support of operations, including resources forcapital expenditures.
Temporarily restricted - Net assets subject to donor-imposed restrictions. Temporarily restrictednet assets include amounts that are restricted by donors for particular research projects or ed-ucation programs, or are restricted as to the timing of use.
Permanently restricted - Net assets subject to donor-imposed stipulations that are maintainedpermanently by the Foundation. There were no permanently restricted net assets at August 31,2008 and 2007.
3. Cash and Cash EquivalentsThe Foundation considers highly liquid financial instruments purchased with a maturity of threemonths or less when purchased, except those held in its investment portfolio, to be cash equiv-alents. The Foundation maintains cash accounts, which, at times, may exceed federally insuredlimits. The Foundation has not experienced any losses from maintaining cash accounts in ex-cess of federally insured limits. Management believes that it is not exposed to any significantcredit risk on its cash accounts.
4. Contributions and Pledges ReceivableUnconditional contributions, including cash, promises to give, and certain contributed services,gifts in-kind and other assets are recorded as revenue at fair value when received. Conditionalcontributions are recorded when the conditions on which they depend are substantially met.Contributions are recorded, net of estimated uncollectible amounts. Contributions with restric-tions met in the same reporting period as received are recorded as unrestricted contributions.
Unconditional pledges that are expected to be collected within one year are recorded at theirnet realizable value. Unconditional pledges that are expected to be collected in future yearsare recorded at the present value of their estimated future cash flows. Amortization of the re-lated discounts is included in contributions revenue.
5. Allowance for Doubtful AccountsThe Foundation maintains an allowance for doubtful accounts for estimated losses that may resultfrom the inability of its donors to make payments. Such allowances are based upon several fac-tors, including, but not limited to, historical experience and the financial condition of its donors.
6. Investments and Investment IncomeInvestments in equity securities and mutual funds with readily determined fair values and alldebt securities are recorded at fair value. Fair value is determined based upon quoted marketprices. Investment sales and purchases are determined by the specific identification method.Changes in market value of investments are recognized as increases or decreases in unrestrictednet assets unless their use is temporarily restricted by explicit donor stipulations or by law.
Alternative investments (limited liability companies) are stated at fair value as estimated in anunquoted market. Individual investment holdings within the alternative investments may in-clude investments in both nonmarketable and market-traded securities. Fair value of the al-ternative investments is determined by management based on information provided by theinvestment manager. Values may be based on estimates that require varying degrees of judg-ment for investments where readily available fair values do not exist. Generally, fair value re-flects net contributions to the investee and an ownership share of realized and unrealizedinvestment income and expenses. Investments in such funds do carry certain risks includinglack of regulatory oversight, interest rate risk and market risk. Due to the level of risk associatedwith these investments, it is at least reasonably possible that changes in risk factors in the nearterm would affect amounts reported on the statement of financial position.
The Foundation invests in three limited liability companies, which are “funds of funds” (the Funds).The first of these funds (M2) invests mostly in a group of portfolio managers who primarily em-ploy long/short equity strategies, including those involving foreign issuers. The second fund(Event Fund) deploys its assets among a group of portfolio managers, primarily investing in se-curities and other instruments, the market value of which is expected to be meaningfully af-fected by an anticipated event, including distressed securities and long/short equity. The thirdfund (Credit Recovery Fund) has as its investment objective the maximization of total returnover the long term, by deploying its assets primarily among a select group of portfolio man-agers, who invest in companies that have experienced, or are currently experiencing, financialdifficulties as a result of deteriorating operations, adverse legal judgments, or other events,which may adversely impact their credit standing, thus taking advantage of market opportuni-ties and pricing inefficiencies between the perceived value of an obligation and its market value.
Income earned from investments, including realized and unrealized gains and losses, is recordedon the net asset class owning the assets, based on the trade dates for the investments.
7. Charitable Gift AnnuitiesThe Foundation has several charitable gift annuities which are arrangements between donorsand the Foundation in which the donors contribute assets to the Foundation in exchange for apromise by the Foundation to pay a fixed amount for a specified period of time to the donors orto individuals or organizations designated by the donors. The fair value of the asset is recordedas a charitable gift annuity and the corresponding liability to the donors is recorded as a gift an-nuity liability at the present value of its future payments in the statement of financial position.
8. Charitable Remainder TrustsThe Foundation has been named as the sole beneficiary in several charitable remainder trustsheld by third party trustees. A charitable remainder trust is an arrangement in which a donor es-tablishes a trust with specified distributions to be made to a designated beneficiary or benefi-ciaries over the trust’s term. The Foundation will receive its share of the assets remaining uponthe termination of the charitable remainder trust.
The Foundation has recorded the estimated present value of its interest in the trusts’ assets ascharitable remainder trusts and contribution income, in accordance with the terms of the trusts.
9. Furniture, Equipment and Leasehold ImprovementsFurniture and equipment are recorded at cost or, if donated, at fair value on the date received.Depreciation is computed using the straight-line basis over the estimated useful lives of theassets ranging from three to ten years. Leasehold improvements are amortized over the re-maining lease term or the estimated life of the improvements, whichever is shorter.
10. Research Grants PayableThe Foundation records appropriations for research grants as a liability and expense after ap-proval by the National Board of Trustees based upon (i) the recommendations of the Board’s ad-visory committees called the National Scientific Advisory Committee’s Grants ReviewCommittee, the Research Training Awards Program Committee the Research Initiatives Com-mittee, and any appropriate ad hoc review committees, (the Review Committees); and (ii) theavailability of funding. Grants are approved for a one year term with conditional annual renewalperiods up to two years. The only exceptions are the core administrative and data managementcenters for both the Clinical Research Alliance and DNA Bank, which are long-term commit-ments. However, these awards are subject to existing grant policies and procedures, andprogress reports are reviewed annually in accordance with these policies. The grants are con-ditional based upon the receipt, review and approval of annual progress reporting from thegrant recipients by the Review Committees. The annual grants are disbursed quarterly over theperiod for which they have been approved. Conditional grants are recognized in the period inwhich the terms of the conditions are met.
11. Refundable AdvancesThe Foundation receives cash in advance of special events that are to be held after the state-ment of financial position date. These amounts are deferred until the event occurs, since theyare refundable if the event is subsequently canceled.
12. Contributed AirtimeThe Foundation receives considerable in-kind contributions primarily in the form of donatedpublic service announcements on television and radio stations. The value of such in-kind con-tributions, based upon information provided by third-party media services, is reflected in theaccompanying statement of activities as contributed airtime revenue and health professionaleducation and public information program service expense.
13. VolunteersOther than the Committees, a number of volunteers, including members of the National Boardof Trustees, have made significant contributions of time to the Foundation’s policy-making, pro-gram and support functions. The value of this contributed time does not meet the criteria forrecognition of contributed services contained in SFAS No. 116, Accounting for Contributions Re-ceived and Contributions Made, and accordingly, is not reflected in the accompanying state-ment of activities.
14. Tax-Exempt StatusThe Foundation is a not-for-profit voluntary health organization exempt from federal incometaxes under Section 501(c)(3) of the Internal Revenue Code (the Code) and has been classifiedas a publicly supported charitable organization under Section 509(a)(1) of the Code and quali-fies for the maximum charitable contribution deduction by donors. Contributions to the Foun-dation are tax deductible within the limitations prescribed by the Code. The Foundation is alsoexempt from state and local taxes under similar statutes.
15. Functional Allocation of ExpensesExpenses that can be directly identified with the program or supporting service to which theyrelate are charged accordingly. The costs of providing various programs and supporting serv-ices have been summarized on a functional basis in the statement of activities. Accordingly,certain costs have been allocated among the programs and supporting services benefited.
16. Use of EstimatesThe preparation of the financial statements in conformity with accounting principles generallyaccepted in the United States of America requires management to make estimates and as-sumptions that affect the reported amounts of assets and liabilities, and disclosure of contin-gent assets and liabilities at the date of the financial statements and the reported amounts ofrevenues and expenses during the reporting period. The most significant management esti-mates and assumptions relate to the determination of allowances for doubtful accounts forpledges receivable, alternative investment values, functional allocation of expenses, the pres-ent value of the Foundation’s assets in charitable remainder trusts and useful lives of fixed as-sets. Actual results could differ from those estimates.
17. Pending New Accounting PronouncementsIn September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. This new standardprovides guidance for using fair value to measure assets and liabilities. SFAS No. 157 applieswhenever other standards require (or permit) assets or liabilities to be measured at fair valuebut does not expand the use of fair value in any new circumstances. The standard clarifies thatfor items that are not actively traded, such as certain kinds of derivatives, fair value should re-flect the price in a transaction with a market participant, including an adjustment for risk, notjust the organization’s mark-to-market value. SFAS No. 157 also requires expanded disclosureof the effect on earnings for items measured using unobservable data.
Under SFAS No. 157, fair value refers to the price that would be received to sell an asset or paidto transfer a liability in an orderly transaction between market participants in the principal mar-ket for the asset or liability or, in the absence of a principal market, the most advantageousmarket for the asset or liability. In this standard, the FASB clarifies the principle that fair valueshould be based on the assumptions market participants would use when pricing the asset orliability. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. Earlier ap-plication is encouraged, provided that the reporting entity has not yet issued financial state-ments for that fiscal year, including any financial statements for an interim period within thatfiscal year. The Foundation intends to adopt SFAS No. 157 as it applies to its fiscal year endingAugust 31, 2009 and is evaluating the impact.
In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assetsand Financial Liabilities - Including an Amendment of FASB Statement 115. SFAS No. 159 permitsentities to choose to measure certain financial instruments and other items at fair value. The ob-jective is to improve financial reporting by providing entities with the opportunity to mitigatevolatility in reported earnings caused by measuring related assets and liabilities differentlywithout having to apply complex hedge accounting provisions. SFAS No. 159 is effective for fis-cal years beginning after November 15, 2007. The Foundation is currently evaluating whether toadopt SFAS No. 159 as it applies to its fiscal year ending August 31, 2009.
In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in IncomeTaxes (FIN 48). FIN 48 requires that a tax position be recognized or derecognized based on a“more likely than not” threshold. This applies to positions taken or expected to be taken in atax return. In December 2008, the FASB issued FASB Staff Position (FSP) FIN 48-3, Effective Dateof FASB Interpretation No. 48 for Certain Nonpublic Enterprises. FSP FIN 48-3 permits an entitywithin its scope to defer the effective date of FASB Interpretation 48 (Interpretation 48), Ac-counting for Uncertainty in Income Taxes, to its annual financial statements for fiscal years be-ginning after December 15, 2008. The Foundation has elected to defer the application ofInterpretation 48 for the year ending August 31, 2008. The Foundation evaluates its uncertaintax positions using the provisions of FASB Statement 5, Accounting for Contingencies. Accord-ingly, a loss contingency is recognized when it is probable that a liability has been incurred asof the date of the financial statements and the amount of the loss can be reasonably estimated.The amount recognized is subject to estimate and management judgment with respect to thelikely outcome of each uncertain tax position. The amount that is ultimately sustained for an in-dividual uncertain tax position or for all uncertain tax positions in the aggregate could differfrom the amount recognized. The Foundation is evaluating the impact and does not believe itsfinancial statements include any uncertain tax positions.
Financial Statem
ents
25NOTE B–RESEARCH GRANTS
At August 31, 2008 and 2007, the accompanying statement of financial position includes re-search grants aggregating $8,641,721 and $10,409,191, respectively, which are payablewithin one year.
Research expense on the statement of activities is net of $2,451,783 and $432,497, repre-senting return of prior year grants for terminations or refunds for the years ending August31, 2008 and 2007, respectively. Research grants and awards disbursements total$15,508,006 and $14,444,464 for the years ended August 31, 2008 and 2007, respectively.
In addition, the Foundation has unpaid conditional grants outstanding of $11,911,777 and$19,736,431 at August 31, 2008 and 2007, respectively, which are payable upon satisfactionof the underlying conditions and, therefore, they are not recorded in the statement of fi-nancial position.
NOTE C–PLEDGES RECEIVABLE
Pledges receivable, discounted to present value, are due to be collected as follows: 2008 2007
Within one year $3,253,947 $2,702,709One to five years 1,807,772 2,874,000More than five years 370,000 380,000
5,431,719 5,956,709Discounted to present value (at rates ranging from 2.17% to 7.00%) (148,988) (259,780)
Net present value 5,282,731 5,696,929Allowance for doubtful accounts (87,000) (213,000)
Pledges receivable, net $5,195,731 $5,483,929
NOTE D–CHARITABLE REMAINDER TRUSTS
At August 31, 2008 and 2007, the Foundation has remainder interests in several irrevoca-ble charitable remainder trusts. The present value of the Foundation’s future interests inthese charitable remainder trusts, which amount to $311,920 and $341,872 at August 31,2008 and 2007, respectively, have been recorded as charitable remainder trusts, in accor-dance with the terms of the trusts and are included in temporarily restricted net assets. Thepresent value of the trusts was calculated using a discount rate of 5.8% at August 31, 2008and 2007, respectively. Change in value of the charitable remainder trusts was $29,952 and$22,838 in 2008 and 2007, respectively.
NOTE E–INVESTMENTS
The fair value of investments at August 31, 2008 and 2007 consisted of the following:2008 2007
Cash and cash equivalents $1,914,866 $2,118,006Marketable securities 7,836,685 6,401,086Limited liability companies 1,374,979 1,155,795U.S. Treasury bonds – 3,971,135Other – 262,649
Total investments $11,126,530 $13,908,671
NOTE F–FURNITURE, EQUIPMENT AND LEASEHOLD IMPROVEMENTS
Furniture, equipment and leasehold improvements consisted of the following at August31, 2008 and 2007:
2008 2007
Furniture and fixtures $381,418 $595,529Equipment 285,681 285,681Computer equipment 1,051,025 2,157,717Leasehold improvements 684,523 684,523
2,402,647 3,723,450Less: accumulated depreciation (1,374,410) (2,430,589)
Fixed assets, net $1,028,237 $1,292,861
Depreciation and amortization expense for the years ended August 31, 2008 and 2007 was$433,281 and $427,023, respectively.
NOTE G–COMMITMENTS
1. Operating leasesThe Foundation leases office space for the National Office and Chapter offices in variouscities throughout the country. These leases expire at various dates and have renewal optionsranging from three to five years. The volunteer affiliate has no rent commitments. The leasesprovide for increases in future lease payments. The minimum annual rental commitmentsunder operating leases are as follows:
Year ending August 31,
2009 $1,042,5442010 871,6392011 582,3772012 496,4002013 413,970Thereafter 34,560
Total $3,441,490
Rent expense was approximately $1,226,000 and $1,149,000 for the years ended August 31,2008 and 2007, respectively.
2. Capital Lease ObligationThe Foundation leases certain equipment under an agreement classified as a capital lease.The equipment is included in furniture, equipment and leasehold improvements on the bal-ance sheet and depreciation of the assets is included in depreciation expense. The re-maining lease obligation of $37,121 is due in the year ended August 31, 2009.
NOTE H–PENSION PLAN
The Foundation has a defined contribution pension plan. Employees are eligible to partic-ipate in the plan upon hire, with full vesting upon one year of service. Contributions to thisplan are 5% of the participating employees’ salaries. The Foundation’s contribution to theplan was approximately $336,000 and $269,000 for the years ended August 31, 2008 and2007, respectively.
NOTE I–TEMPORARILY RESTRICTED NET ASSETS
Temporarily restricted net assets are available upon satisfying the following restrictions: 2008 2007
Purpose restrictionsResearch programs $3,660,476 $4,927,640Education programs 1,296,694 915,638Time restrictions 463,869 636,974
$5,421,039 $6,480,252
NOTE J–NET ASSETS RELEASED FROM RESTRICTION
For the years ended August 31, 2008 and 2007, net assets were released from donor re-strictions by incurring expenses satisfying the restricted purposes specified by donors orthe passage of time as follows:
2008 2007
Research programs $9,351,561 $4,949,056Education programs 2,016,788 226,116Time restrictions 169,045 –
$11,537,394 $5,175,172
NOTE K–RELATED PARTY TRANSACTIONS
During the years ended August 31, 2008 and 2007, the Foundation held investment assetswith an investment company. A Foundation trustee was employed as a Vice President of thecompany until July 17, 2008. All investments of the Foundation are held by this companyand fees paid by the Foundation to the company were approximately $128,000 and $78,300for the years ended August 31, 2008 and 2007, respectively. The company was selected bythe Board of Trustees after review of other available options.
The Foundation receives contributions from members of the Board of Trustees. For the yearsended August 31, 2008 and 2007, respectively, members of the Board of Trustees con-tributed $178,548 and $127,678.
Included in pledges receivable was $1,578,305 and $3,264,684 due from related partiesfor the years ended August 31, 2008 and 2007, respectively.
The Foundation uses a website to process online contributions for special events. This web-site is affiliated with a member of the Foundation’s Board of Directors. The Foundation ischarged a 6% processing fee on all transactions. For the year ended August 31, 2008 totalfees paid were approximately $249,000.
NOTE L–CONTINGENCIES
The Foundation is subject to various claims and legal proceedings arising out of the ordinarycourse of business. Management believes the resolution of claims and pending litigationwill not have a material effect, individually or in the aggregate, on the consolidated finan-cial position of the Foundation.
Friends of CCFAWe gratefully acknowledge the support of the donors who contribute to the Crohn’s& Colitis Foundation through the Combined Federal Campaign, State Employee campaigns, the United Way, and all other federated campaigns in the workplace.
The Crohn’s & Colitis Foundation extendsits deepest regrets to any donor whosename may have been inadvertently omittedfrom this list.
INDIVIDUALS AND FOUNDATIONS
Roberta & Irwin ChafetzArie and Ida Crown MemorialEllen & Daniel CrownJay and Ann DavisRichard DavisMr. & Mrs. Lawrence FinkelsteinMr. & Mrs. Melvin FinkelsteinGet Your Guts In GearMark & Diane GoldmanGreenspun Family FoundationMr. & Mrs. Brian GreenspunMr. & Mrs. Daniel GreenspunMs. Susan Greenspun FineMr. & Mrs. Leonard LitwinMankoff Family FoundationJeff & Staci MankoffRon & Joy MankoffBarbara & Fred MillerAbby ModellRobin & Mitchell ModellShelby & William ModellLisa & James A. PappasCecile PattersonSuzanne & Irwin RosenthalThe Bruce and Cynthia Sherman Charitable
Foundation, Inc.The William Stamps Farish FundDaniel L. StoneMichelle & Howard SwarzmanMichele & Steven Sweetwood
Anonymous Donor, Mid-America ChapterAnonymous Donor, Southwest Ohio ChapterJane & Michael Axelrod The Jacob & Hilda Blaustein Foundation, Inc.Ethel Wilson Bowles and Robert Bowles
Memorial FundBenjamin G. DarnellIsabelle & Donald DiRenzo, Sr.Estate of David E. DrexlerEstate of Gerald W. DulkisThe Samuel R. Dweck FoundationMr. & Mrs. Maury EttlesonJoan FalkLori and Howard FenstermanMrs. Phyllis FriasMr. & Mrs. Jeffrey GaleThe Galen Family FoundationThe Gillman Family - Shaldine, Richard,
Marc, Sloane, Scott, & AndreaMonte & Rita GoldmanMr. & Mrs. Mark JamesSusan & Michael KerrF.M. Kirby Foundation, Inc.Debbie & Jeffrey H. MargolisArthur & Jayn MarshallMs. Cari MarshallMr. Todd MarshallPamela & Edward S. Pantzer
Premier Donors $250,000 +
Patrons $100,000 +
Friends of CCFA
27Cathy & Peter Pappas, Sr.Irene and Peter Pappas, Jr.Elvin & Janet PriceMs. Michele RaphaelEstate of Abraham RichEstate of Judith SaphirMrs. Ilene SchwartzElaine & Alan Weiler
Anonymous, Greater Washington D.C./Virginia Chaper
Anonymous, Illinois Carol Fisher ChapterPauline Arama-Olsten & Stuart OlstenMr. & Mrs. Bruce R. BehrenLeo & Louise BenatarNancy & Howard BrownEstate of Steven ColtLeon & Toby CoopermanMr. & Mrs. Edgar M. Cullman, Sr.Elissa & Edgar M. Cullman, Jr.Rhondell & Glen Domilici Mr. Arthur J. EpsteinThe Fondren FoundationGordon & Regina FordEstate of Phillip GoosMr. & Mrs. Steven L. GringauzMr. & Mrs. Jay and Dawn JohnsonKoss Foundation, Inc.Mr. & Mrs. Michael KossMr. & Mrs. Ronald A. KrancerSeymour & Carol LevinFrancine & Laurance Nagin Susan & Donald NewhouseMs. Agnes NixonMr. & Mrs. Jerry RomanoffMr. & Mrs. Gary ScharfDr. & Mrs. Victor ScharfMarshall Sparberg, M.D.Linda Tallen & David Paul Kane Educational
and Research FoundationThe Wasie FoundationMrs. Joan WheelerThe Wilbur May FoundationThe Michael Yendick Foundation for Children
Anonymous, Houston Gulf Coast/SouthTexas Chapter
Bonnie & Charles AlterSteven BashMichele & Paul BergerMr. & Mrs. Fred BermanMrs. Irene BloomsteinPatrick & Greggory BurkMrs. Elizabeth CalhounThe Community Foundation For The National
Capital RegionMr. & Mrs. Joel E. CutlerMrs. Vera DeutschMrs. Sandra M. EdgerleyThe Lester M. & Sally Entin FoundationMr. & Mrs. Stephan Feder
Guardians $50,000 +
Fellows $25,000 +
Nina & David FialkowBruce & Dale FrankelEstate of James & Mary FranklinSenator Charles Fuchillo Diane & Barry GanzIrwin and Joan Geduld Family FoundationThe Gelber FoundationLisa and Douglas Goldman FundRichard and Rhoda Goldman FundElaine & Michael Stephen GoldsteinMr. Alan GradJill & Robert HobermanHorwitz Family Memorial FoundationMr. & Mrs. John ImbesiMr. & Mrs. Jay and Dawn JohnsonJeffrey JustinKassner Family FoundationLeo & Barbara KarasZach & Jessica KerrKaren & Richard KleinmanJackie Tyree Kos & Al KosElizabeth KrulikMr. Murray KushnerMr. & Mrs. Tom KuzmaMrs. Claire LevineMs. Holly LissnerMacDonald Peterson FoundationAlma Lee MarshallDavid Maus FoundationMc Ateer Memorial Golf FundMichael and Rhonda McCarthyJohn P. McGovern FoundationMr. & Mrs. Benson R. McLendon, Jr.Mrs. Elsie MillerTed MoudisCaroline & Anthony NastasiMr. & Mrs. James A. Parrish, Jr.Ms. Betty J. PowersMary & Bruce RabinerMrs. Violet G. RaumMr. & Mrs. Donald RechlerMitchell & Deborah RechlerMrs. Shelley RedstoneDr. David M. RosemanThe Scottish Rite Foundation of Missouri, Inc.Joel & Lauren ShapiroLouis & Emily ShapiroSam & Gina ShapiroKay & Richard ShermanSilicon Valley Community FoundationSenator Dean SkelosMr. Lester SmithEstate of Anita StaufferMr. & Mrs. Steven StrasserDr. & Mrs. Paul TartelMr. & Mrs. Van Van AukenMeredith Waldner SternStephen WaldnerMr. & Mrs. Holland WalshMr. Bruce WassersteinLeon & Marysue WechslerStephen B. WechslerYahoo! Employee Foundation
Mr. & Mrs. Murray BeerGreg BerkEstate of Adele BlankMr. & Mrs. Michael BrownMr. & Mrs. John BurnsKenneth CarmelMr. Frank CasalMitzi CloudThe Cowles Charitable TrustMr. & Mrs. Theodore CutlerDaniell Family Foundation Inc.Diamondston Foundation, Inc.Brian DonaghyLester M. & Sally Entin FoundationArt & Marcy FalconeJames FitchFoundation For Research of Pediatric ColitisFutures & Options for Kids, Inc.Lisa & Tony GerratoAlex GetelmanThe Giant Eagle FoundationGary GoldmanMr. & Mrs. Robert GoldsteinMr. & Dr. Joe GuggerMs. Hanna HombordyMr. & Mrs. Donald JacklinEstate of Kathryn Ann JacklinAllen & Dana JacobsonMs. Audrey S. KatzMrs. Lenora KleinKnoxville Christian Community FoundationThe Kupferberg FoundationMr. & Mrs. Don LaRoccaThe Lance Robert McLendon FoundationEve MilsteinElyse & Michael NewhouseNew York Yankees FoundationMr. & Mrs. S. Christian Nielsen, IIIMr. & Mrs. Ira PittelmanThe Herman T. & Phenie R. Pott FoundationBruce & Mary RabinerMr. Robert RaphaelMr. & Mrs. Jan RaskMr. & Mrs. Sumner RedstoneSamantha & David RipkaDr. & Mrs. James RooneyEllen J. Scherl, M.D.Mr. & Mrs. Malcolm SchwartzThe Sidgmore Family FoundationDr. Harry SobelTammi & Mark StempelMr. & Mrs. David TaffetMr. & Mrs. Arthur TauberThe Tudor Foundation Inc.J. Robert and Diane WardAnthony WestrickThe Wishlist FoundationCarol & Joseph Wolfer
Ms. Amy AbramsAlbert and Margaret Alkek Foundation
Benefactors $10,000 +
Sponsors $15,000 + Ms. Angela AntonArthur BackallMr. & Mrs. Joel BarnettMr. Edward M. BernsteinBeta Sigma PhiBogen Family Charitable TrustBoston FoundationJulie & Paul BrandesDr. Martha D. BrownKim CalvoLisa ChanoffMr. Stanley I. CheraMr. & Mrs. Dennis CicconeDiane & Peter CosentinoMr. & Mrs. Percy CreuzotEstate of Doris CurtisScott & Kathleen DalecioKimberly DeLapeAlan & Lorie DelkMr. & Mrs. Steven DrookerEastern Bank Charitable FoundationLarry ElinsJ. A. & Isabel M. Elkins FoundationFeil Family FoundationSally & Steve FeldbergMr. Jerry D. FieldsMark & Randi FisherMrs. Patricia D. ForbesMr. & Mrs. Richard FrankelMr. Jay Furman & Dr. Gail FurmanMorris & Gertrude Furman FoundationThe Berenice Gates Hopper Family FundMr. Alex GetelmanGiarla & Michelson Charitable FoundationGilbert Family FoundationMr. Howard GleicherMr. Les GoodsteinMr. & Mrs. Jim GordonReuben & Mollie Gordon FoundationStone GossardThe Greater Cincinnati FoundationGrebow Family FoundationThe George & Mary Josephine Hamman
FoundationRobert & Mary Sue HawkJill HellerHellman Family FoundationJanet & Arthur HershaftDavid Horing Ms. Helene HouleMr. & Mrs. Michael HubbeEstate of Linda JellenikMr. & Mrs. Howard JessenMr. & Ms. Louis KaitzThe Kaplen FoundationSK Children’s CharitiesMark & Dawne KaufmanThe Louis J. and June E. Kay FoundationKirkland & Ellis FoundationMr. & Mrs. Richard KlapmanMr. & Mrs. Seth A. KlarmanMindy Kristel-WolinskyS&C Kushner Family FoundationKaren & William LauderThe Lehman Brothers Foundation
Ms. Beatrice LempelSaul & Eleanor Lerner FoundationMr. Al LoverdeMr. Thomas LevyLucinda LoyaLori LupiniMr. & Mrs. Harold MatznerAndrew & Lydia MaysMcAteer Family TrustMike McCready & Ashley O’ConnorJoan & Peter McKeeJason & Amy McLevaineMr. Shaun MeehanMs. Katherine MerageMr. & Mrs. Wallace D. MersereauMr. Thomas MessinaMr. A. Chris Meyer, Jr.Middle Tennessee Electric Membership
CorporationDiane & Stanley MillerMills Family Charitable FoundationMrs. Ioanna MooreThe Mr. 59 FoundationLaura Ellen & Robert MugliaMr. John Nasseff & Ms. Helene HouleAlbert & Angela NassiRon PetrichMr. Kevin PlankRaymond QuartararoDr. & Mrs. James M. RabbMrs. Ashley ReiflerRandi & Dennis RieseMr. & Mrs. Joseph RosenMr. David S. RosenbergIris & Walter RubensteinMr. & Ms. Mark H. RubinMr. Michael G. RubinMr. Morton RudermanThe San Diego Foundation Myron Feinberg
Endowment FundJeffrey & Nancy SchondorfMr. & Mrs. William SchulderDonna & Marvin SchwartzEstate of Herman and Blanche SelwynMr. & Mrs. Mark SeruyaMrs. Mary SextonLester & Edna Shapiro Family FoundationMr. & Mrs. Steven M. ShapiroThe Harvey Silverman Foundation, IncThe Elwood & Carol Simon Family FoundationThe Sidney, Milton and Leoma Simon
FoundationWarren & Roberta SirzykMr. & Mrs. Michael SobeckiDr. & Mrs. Max A. SobelThe Lawrence & Lillian Solomon Fund, Inc.Mr. Randy StilleyMr. Edward StreimValerie SwarbrickCarmella & Peter TullyEdward & Scott TurenA. Raymond TyeMr. David M. UnderwoodCaron & Michael VanariaJames & Kathryn Vaughan
Friends of CCFA
29Wal-Mart FoundationThe Walsh FoundationThe Jamison Williams FoundationIrma & Sidney WinokerLois Robbins Zaro
Anonymous, Fairfield/Westchester ChapterAnonymous, Greater Los Angeles ChapterAnonymous, Greater New York ChapterAbrams Foundation, Inc.Mr. & Mrs. Jim AbramsStanford & Joan AlexanderThe Alkek and Williams FoundationDr. Sharon AlloyAmerican Dream Foundation Inc.Fred C. and Katherine B. Andersen FoundationMs. Rhea AndersonThe Annenberg FoundationThe Applebaum Foundation Inc.Ms. Debbie AttanasioMeg & Jay AxelrodMr. & Mrs. Arthur BairdDavid & Gwen BakerMr. & Mrs. Ralph BarnettMrs. Linda C. BarryJudy & Joel Bauer, M.D.Mr. Eric D. BeckerMrs. Janine BehrmanFerdinand E. BelgaMr. Ward BennettDr. & Mrs. Michael BergerDavid & Betty BerkmanMr. Jeffrey BerkowitzMr. Xerxes BhoteAngela BiggarMr. & Mrs. Christopher BillmeyerBishop Family FoundationMr. & Mrs. Howard BlattMichael & Nina BlechmanMr. Gerald BlockMr. & Mrs. Fred BlumeEmployees Community Fund of Boeing
St. LouisDavid & Georgia BoutwellThe Braeside FoundationMrs. Judy BriskinMr. Joshua BroderThe Brooks Family FoundationDr. and Mrs. David BrownMrs. Eunice BrownMr. & Mrs. John BrownMr. & Mrs. Andrew BruckerMr. Craig CaffarelliMr. Frank CalifanoCammarata Family FoundationMr. & Mrs. Daniel D. CantorMr. Michael CappelliThe Caring FoundationEula Carlos Foundation, Inc.Paul Casey & FamilyCynthia Cassandro, R.N., B.S.N.Paul & Ruth ChosidMr. Lance Chudnow
Associates $5,000 +
Clarcor FoundationMr. & Mrs. John ClearyMr. & Mrs. Jerry CohenMilton L. Cohen & Norma M. Cohen Family
Foundation Inc.Mr. & Mrs. Stanley L. CohenColdwell Banker Residential Brokerage
Community FoundationMr. & Mrs. David ColmanSally ConnollyMilton Cooper Foundation, Inc.Dr. Richard CorcoranPeter CosentinoMr. & Mrs. Howard CowanGerald CroanMr. Rod CrosbyCubs Care, a fund of the McCormick Tribune
FoundationHelen R. CykerMark F. DaltonDaniels Family FoundationMr. & Mrs. Sean DanyThe Davenport-Hatch FoundationBenjamin & Frances David FoundationMr. & Mrs. Dennis D. DormanDorskind Family FoundationMr. & Mrs. Robert DubinMr. & Mrs. Edward DunlapThe Dyson FoundationThe Elmezzi Private FoundationRuth Epstein Schuler FoundationJuliet FadelyDavid & Ruth FalkensteinThe Fan Fox and Leslie R. Samuels
Foundation Inc.Fant FoundationMrs. Shelley FehrenbachDr. Allan FeingoldMs. Judy FelsenthalCarl FerraroMr. Joe FeshbachMs. Michelle FilteauMr. & Mrs. Richard FineburgSusan and Leonard Feinstein Family
FoundationMr. Bruce J. FingeretThe Herman & Jerry Finkelstein FoundationMs. Harriet M. FinnMr. & Mrs. Michael FrancisMr. and Mrs. Michael FranciscoVirginia Friedhofer Charitable TrustFriedman Supporting FoundationPhilip M. FriedmannMrs. Pauline FrohlickMr. & Mrs. Nathan FrootThe G&A Foundation Inc.Ms. Melissa GallagherDavid GantosMr. & Mrs. Andrew S. GarbThe Eliot J. Garber Foundation Inc.Mr. Michael GenattAllison GerberMr. Richard GeswellMr. & Mrs. Albert GherloneMr. and Mrs. Ned Gill, III
Brandon GillmanMr. Laurence T. GinsbergGlaser Progress FoundationMr. & Mrs. Robert GlassMr. & Mrs. Morton GleicherMr. & Mrs. Joel GlickmanRobert Glickman, M.D.Ms. Stana GnatovichMrs. Judy GoldEarl & Suzanne GoldbergSamuel Goldberg & Sons FoundationMr. & Mrs. Jonathan GoldmanCarol H. Goldsmith & Aaron GoldsmithSteve and Katie GoodmanSuzanne H. GorabMr. & Ms. Gerald T. GossMr. & Mrs. Warren GrantPamela GravenMs. Susan Zises GreenMr. & Mrs. Alan GreenbergLewis Greenwood FoundationMrs. Bonnie GreggeLinda & Donald GrossMr. Ira GrossMr. & Mrs. Michael GrossMrs. Ellen GrossmanGUESS? FoundationStaci GuraMrs. Jill HaberMr. Ed HaikenHalpryn Family Foundation Inc.Estate of Richard HauserHeller Bros FoundationMr. Dan HellerMrs. Ruth HendelMichelle & Scott HerbertMr. & Mrs. Robert HernandezBetty & Rodger HessMs. Margaret HivelyTim HolinerMs. Daisey HolmesDouglas HorlickThe Ralph and Genevieve B. Horween
FoundationMr. & Mrs. G. B. Howard, IVMr. & Mrs. Henry Hoyt, Jr.Mr. Richard HuntMr. & Mrs. Joseph J. IsraelJune JacobsMr. and Mrs. Robert JasperMr. Joe JohnsonMr. & Mrs. Paul T. JonesMr. Peter JosephNorman & Lisa JudahAlyne & Abbey KaplanMs. Jane KappSamuel and Rebecca Kardon FoundationKarp Family FoundationMs. Martha KarshRebecca KeithMr. & Mrs. Michael KempnerMr. & Mrs. Eugene KestenbaumThe David Kimmel FoundationMs. Carrie KirkMs. Marjorie Klayman
The Harry Kletter FamilyLouis and Rose Klosk FundKnell Family FoundationKnez Family Charitable FoundationCheryl KnippenbergSteve & Eydie KooninMr. & Mrs. Gerald KordeMr. Robert S. KorffMrs. Amy KovacMr. Richard KuciSteve & Cathy KuranoffBroh & Tracy LandsmanCorinne LangerThe Lauder FoundationMs. Helen H. LeeEstate of Bernard Leeb Mr. & Mrs. Eric & Liz LefkofskyLegg Mason Charitable FoundationMr. Stew LeonardMs. Dorothy D. LeveyMr. & Mrs. Abner LevineMr. Jeffrey Libert & Ms. Martha BrownMr. Michael LimanMr. & Mrs. Martin LindenfeldDorina LinkMaurice LipnickMr. & Mrs. Barry H. LippmanMr. Louis J. LombardiMr. Sheldon LustigmanDr. & Mrs. Mitchell LynnMr. & Mrs. Russell MaddoxMadison Charitable Foundation, Inc.Mr. & Dr. Brian MaierMs. Rochelle MaizeMr. & Mrs. Samuel B. MarcusMr. & Mrs. William M. MarcusKate & Joel MargoleseErica Marieb, Ph.D.Dr. & Mrs. Bradley MarshJames G. Martin Memorial TrustSharla MartinezMrs. Cynthia MarxMarx-Better FoundationThe Lester & Grace Maslow Foundation Inc.Maxim Charitable FoundationMary & Michael McDonoughJames & Swan McKnightAri MeiselDr. & Mrs. Samuel MelamedMs. Ellen MichelsonMrs. Debra MichielsJoshua and Pamela Miller Family Gift FundLaura MillerJames MillsMr. & Mrs. Arthur ModellMs. Susan MolaskyMr. & Ms. Hernando MoraMr. J. Roger MorrisonMoss Foundation, Inc.Philip S. MullerMrs. Alice MuskovitzMr. Alan NadlerNamoff Family FundNewell FoundationBob & Barb Nieder
The William F. O’Connor FoundationThe Orchard Farm FoundationOrtega FoundationKathryn May Paben Family Charity TrustGreg & Janet ParkerKathleen & James L. Patton, Jr.Susan PeckWayne & Christine PerryMs. Joyce PerskyGary & Jill PodellJ. Neal & Martha PurcellQuest Diagnostics Foundation, IncMr. & Mrs. Martin J. RabinowitzJan RaskMs. Karen RasmussenDavid & Cecelia RatcliffeMilton R. Ratner FoundationMr. & Mrs. Robert ReinerRich Foundation, Inc.Ms. Rosalyn C. RichmanDr. Marcia Robbins-WilfMs. Jill RobertsMr. & Mrs. Mitchell RobertsMr. Philip Roberts & Ms. Alison NesmithMr. Richard I. RomanoffDr. Jose Roque, M.D.Mr. & Mrs. Hal RosenbluthRoss Family FundRenee & Edward Ross FoundationEdwin & Louise RothbergMr. & Mrs. Stuart RothenbergMr. Eric RothfeldRothman Family Foundation Mr. & Mrs. Marc RowanMr. Tim RussertMr. & Mrs. Jerry RuthmanMr. Edward G. RyanMrs. Selma RyaveMr. Kenneth SacksDr. & Mrs. Don SaferSampson Family Charitable FoundationMr. & Mrs. Norton SarnoffDr. Howard ScaloneTina Hoffman & Geoff SchechterMrs. Jane K. ScheinfeldCharles & Mildred Schnurmacher
FoundationMr. & Mrs. Glenn G. SchreinerDr. & Mrs. Ron and Susan SchwartzMr. Scott SchweighauserMr. Jeremy SclarAnita ShapiroEllen & Steve ShapiroMr. Harry S. ShapiroMr. & Mrs. Jerry ShapiroMr. Ed SheaGeorge L. Shields Foundation, Inc.Ms. Michelle ShopennMrs. Barbara ShurginMr. Mace SiegelJudy A. SigalMr. & Mrs. Jeff SilversteinMarc A. Silverstein, M.D.Mr. & Mrs. David SimonMr. & Mrs. Gary Sinderbrand
Mrs. Karen S. SingerMr. & Mrs. Alfred SlifkaMr. & Mrs. Reed SlogoffRobbyn Sockolow, M.D.Mr. & Mrs. Gary N. SolomonMr. & Mrs. Theodore G. SolomonMr. & Mrs. Martin SpectorTerry Gillespie & John StantonMs. Nancy G. SteirBurton & Barbara SternMr. Frederick StowMr. & Mrs. Herbert StraussThe Rose & Bernard Strauss Foundation Inc.Stronge Family FoundationMr. Greg SulgerMr. Sidney SwartzMrs. Mary S. SweeneyMr. Evan TannorTCF FoundationMr. & Mrs. Vincent TeseThe Thompson FoundationMr. & Mrs. Hall ThompsonMr. & Mrs. A. Richard TischlerScott & Tina TracyMr. & Mrs. Thomas TuftMrs. Patricia B. TurenMs. Martha TurnerMarshall & Terri TurnerMr. & Mrs. Thomas B. Tyree, Jr.William F. & Barbara TyreeMr. & Mrs. Bruce TysonMr. & Mrs. Dick ValenteVictory Hope FoundationMeredith VieiraMr. Marc VigodMr. John VissicchioVitalogy Health FoundationStephen VolkMr. & Mrs. Robert WachsteinMr. & Mrs. Gordon WaldorfMr. & Mrs. John WalshWeil, Gotshal & Manges Foundation Inc.Mr. & Mrs. Jim H. Weiss, Sr.Wells Fargo Community Support CampaignMr. Bruce WesselJeffrey & Cynthia WiesenfeldMr. & Mrs. Robert D. WildsteinMr. Michael C. WilkinsNell Williams Family FoundationBarry D. Winston, M.D.Mr. Ronald WinstonCol. & Mrs. Charles H. WittrockThe Frances Wood Wilson Foundation, Inc.Ms. Tania WoodWyse Family FoundationMr. & Ms. Paul ZagariaMrs. Lynn ZimmerMr. Lawrence ZimmermanMrs. Cathy W. Zises
Friends of CCFA
31CORPORATIONS
Abbott Centocor Ortho Biotech Inc.John Wiley & Sons, Inc.Modell’s Sporting Goods P.J. Mechanical CorpProcter & Gamble PharmaceuticalsShire plcUCB
Abrams, Fensterman, Fensterman, Flowers,Greenberg & Eisman, LLP
Advanced Health Media Fleet HonorariumAccount
Century Club CharitiesConvaTecElan EmbryonRechler Equity PartnersSalix Pharmaceuticals, Inc.TJX Companies
Atlanta Attachment Co.Axcan Pharma USKoss CorporationMcNeil Consumer HealthcareMillennium Pharmaceuticals,
a wholly-owned subsidiary of TakedaPharmaceutical Company
Navellier & Associates, Inc.Otsuka America Pharmaceutical, Inc.PGA Tour, Inc.PNC Wealth ManagementRenegade Swish, LLCSignature BankThe State of New YorkWachovia SecuritiesWolf Popper LLP
AFA Protective Systems, Inc.Alaven Pharmaceutical, LLCBank of AmericaJr. Beta Club of LouisianaBristol-Myers Squibb CompanyCapstone Asset Management CompanyDietz & WatsonGalashiels Fund LimitedIBM Employee Services CenterN B Family LTD Partnership LPNastasi & Associates Inc.OMDUSA, Inc.Prometheus Laboratories, Inc.Shapiro Capital Management Co., Inc.Ximed Digestive Disease Research Center
Fellows $25,000 +
Guardians $50,000 +
Patrons $100,000 +
Premier Donors $250,000 + 386 PAS Partners LLCAdidasAragonAssociated Pipe Line ContractersBeacon Hill Staffing GroupBlank Rome LLPBlue Cross Blue Shield of LouisianaCamp Magic, Inc.Cushman & Wakefield, Inc.Dorland CorporationEdmunds & AssociatesEmageonESPN, Inc.Falcone Group, LLCFutures & Options For Kids, Inc.Gibraltar BankGlobal ImpactGrampy’s Charity OpenHFTP Front Range ChapterJustGiveThe Kamson CorporationKirkland & Ellis, LLPLand Resource Companies, LLCLane Office Furniture, Inc.Los Angeles Lakers, Inc.MedThink CommunicationsNational Distributing Company Inc.New Balance Athletic ShoeNew York Islanders Hockey ClubNew York Knights of the GripThe News CorporationMemorial Hermann Hospital SystemPerry Ellis International, Inc.Pico Holding, Inc.Postgraduate Institute For MedicineRorer Asset Management, LLCSmashbox CosmeticsState Farm Insurance CompaniesTed Moudis AssociatesThomson ReutersTimberland CompanyUnder Armour Athletic ApparelValley National BankVF Services, Inc.Vornado Realty TrustWe Care In IBDThe West Penn Allegheny Health SystemWestern Oil Company, Inc.Westgate Capital Management
AFD Contract Furniture, Inc.Agron, Inc.AIGAll Metals IndustriesAllstate Giving CampaignAmerican Securities Capital Partners, LLCAmerica’s CharitiesThe Bank of New York MellonBilzin Sumberg Baena Price & Axelrod L.L.P.Bloomingdale’sBlue Cross Blue Shield of MA
Benefactors $10,000 +
Sponsors $15,000 + Capital SourceCharitybuzzChubb Federal Insurance CompanyCIBC World Markets Corp.Cleveland Clinic Health SystemCommerce BankCommunity Progress Committee, Inc.Cordis CorporationCostco WholesaleEDSEmployee’s Community Fund of the Boeing
CompanyEverlast Worldwide Inc.Excellent Home Care Services LLCFC ManagementFifth Avenue of LI Realty Assoc.Fisher BrothersFive Star Refrigeration, A/C & Heating LLCFrank Crystal & CompanyGotham Technology GroupHanesbrand, Inc.Heller Ehrman, LLPHollister IncorporatedIllinois Council of Voluntary Health AgenciesIndianapolis Endoscopy CenterJPB EnterprisesKelley Shootout Golf ScrambleKennedy FundingK’NEX Industries, Inc.Lehman BrothersLupini ConstructionM & R Management Co., Inc.Macsteel International USA Corp.Maddox, Hargett & CarusoMajor League BaseballMDA ContractingMednikow JewelersMiddle Tennessee Electric Membership
CorporationMiller PropertiesMONY Life Insurance CompanyN.A.U.S. Charity Fund, Inc.Newmark & Company Real EstateNFL CharitiesNortheast Private Client GroupNova Southeastern UniversityOak Ridge InvestmentsOlsten CorporationPepper Hamilton, LLPPlaza ConstructionReebok International Ltd.Sacramento Area Miata Owners Association
(SAMOA)Sangari USA, LLCSills Cummis & Gross P.C.Six G’s VentureSL Green Realty CorpSouthern CompanyThe Oregon ClinicThe TriZetto Group, Inc.Turner Construction CompanyVandenberg CommunicationsViacom International, Inc.Winick Realty GroupYum! International
Anonymous, Carolinas ChapterAbington Reldan Metals LLCActive Screw & FastenerAdvantage Title Agency Inc.Air Perfect TestingAkerman SenterfittAlcatel-LucentAllied Group Holdings, Inc.Allied NA Ins B’kge of NY, LLCAmSurg Corp.AmTrust BankArapahoe Gastroenterology P.C.Argonne National LabArmitron/E-Gluck CorporationArrisAshlar Mechanical Corp.Asia Five Eight LLCAutoZoneBarnes & Noble, Inc.Baron Capital, Inc.Baylor College of MedicineBDO Seidman LLPBell Sports Inc.Biogen IdecBlackstone Administrative Services
Partnership, LPBNY Mellon Wealth ManagementBoston HeraldBovis Lend Lease Interiors, Inc.Brooklyn Carpet Exchange, Inc.Burklund Distributors, Inc.CAMAC International CorporationThe Cambridge Towel CorporationCampbell Bohn Killin Brittan & Ray, LLCCapital Process ServersCBS CorporationCebert PharmaceuticalsCenterPoint EnergyChaplin’s Automotive GroupChildren’s Health Care Associates, Inc.The Children’s Hospital of Philadelphia
GI Dept.The Clarks Companies, NAColon & Rectal Surgery Associates, LTDComerica Bank-Western MarketConocoPhillipsCosentino Brothers Development LLCDeMartino ConstructionDigestive Health Mgmt, LLCDodge Communication, Inc.Doody MechanicalDurst OrganizationEast Coast AppraisersEclipse Berry Farms, LLCEgan Insurance, Inc./Chubb Insurance Co.El GauchoEMC CorporationEpic Systems CorporationEpiq SystemsErie General Electric Federal Credit UnionEuro RSCG Life ChelseaE-Z-EM, Inc.Fabian Couture Group International, Inc.
Associates $5,000 + First Commercial BankFirst TrustFore Winds Management, LLCFrederick Goldman Inc. Fuller & O’Brien InsuranceGastrointestinal AssociatesGEM Realty Capital, Inc.GI Pathology PLLCGive With LibertyGiven Imaging, Inc.Good, Swartz, Brown & Berns, LLPGreenberg Traurig, P.A.Grossman and Roth, P.A.Grosvenor Capital ManagementHealthPartnersHermann HospitalHoward Hanna Real EstateInovera Bioscience, Inc.INTECH Construction, Inc.InterContinental Hotels GroupInvemed Associates LLCJanover Rubinroit LLCJolie Toi/Sunny HaikJones DayJones Lang LaSalle AmericasJoseph Finn Company, Inc.K.SwissKeyBank National Association Trust DivisionKeystone Electronics Corp.Kiwanis Club of PatchogueKNG Construction Co., Inc.Lewitt, Hackman, Shapiro, Marshall
and HarlanLoeb & LoebM G Engineering, PCM J Soffe Co.Magid Glove and Safety Manufacturing
Co. LLCMarlboro Footworks Ltd.Marriott International, Inc.McMaster-Carr Supply CompanyMedical Mutual of OhioMedica-rentsMeetingAdvice, LLCMemorial HealthcareMeridian Capital Group, LLCMetroPCSMichiana Gastroenterology, Inc.Morgan Stanley Trust, N.A.Morton’sNational Basketball AssociationNational Chef Supply WarehouseNetwork For GoodNew Jersey DevilsNew Jersey NetsThe New York Community TrustThe New York MetsNoble Drilling CorporationOceaneering International, Inc.Olympus America Inc.Option CareOriglio BeveragePapé Material HandlingPark National Bank
Patrolmen’s Benevolent Association of theCity of NY, Inc.
Penava Mechanical Corp.Personal Benefit Services Group, Inc.Pfizer Inc.Pharmaceutical Research and Manufacturers
of AmericaPhiladelphia Stock ExchangePort of Houston Authority of Harris CountyPosternak Blankstein & Lund LLPPricewaterhouseCoopers LLPProgressiveProskauer Rose LLPQuiet Technology AerospaceRedhawk Engineering Inc.Rocky Mountain Gastroenterology
Assoc., PLLCRodman Publishing Corp.Royal Properties, Inc.Russell CorporationRussell Investment GroupS.N. Tannor, Inc.Sedano’s SupermarketsSeminole Tribe of FloridaSerono, Inc.Sheridan HealthcareSigma Tau Pharmaceuticals, Inc.Skechers U.S.A., Inc.South Denver GastroenterolgySoutheast Valley Babe RuthSpicy Pickle Franchising, Inc.Sports AuthoritySSM Design LLPStarbucks Coffee CompanyStark CarpetStat Fire Suppressions Inc.Stearns Weaver Miller Weissler Alhadeff
& Sitterson, P.A.Stone Tower Operating LPStructure Tone Inc.Suram Trading CorporationSutter Home WinerySynovus Financial CorporationTCD Services, LLCTechlab, Inc.Thomas Jefferson University HospitalTiger Capital Group LLCTishman SpeyerTootsies, Inc.Top Banana LLCTransocean Offshore Deepwater Drilling Inc.Trigran InvestmentsTrimarkTurner Broadcasting System, Inc.UBS AGUnited Parcel ServiceUPMCVanderbilt University Medical CenterVariety of GeorgiaVerizonWarrior Roofing Manufacturing, Inc.Whitford CorporationWhitney National BankWhole Foods MarketYale Mortgage Corp.
President’s Corporate CircleWe are proud to acknowledge the members of the President’s Corporate Circle.These dedicated corporate leaders provide significant grants to the Foundation.They are committed to being our partners in progress, and have made possiblemany of the research and education programs discussed in this annual report.
Abbott
Axcan Pharma US
Centocor Ortho Biotech Inc.
Elan
McNeil Consumer Healthcare
President’sCorporate Circle
33
Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical Company
Otsuka America Pharmaceutical, Inc.
Procter & Gamble Pharmaceuticals
Salix Pharmaceuticals, Inc.
Shire plc
Founders Society
Marie AlexanderEstate of Marcia AltmanIsabel AndersonMargaret Ashburn TrustGloria AucottLucielle BachSara BackerLois BaileyLois BakerNancy BakerIra BakstKevin BarnesElizabeth BasshawLois BattilanaRaymond BattilanaMary Benton
Estate of Julius BerkowitzMary BerryEstate of Adele BlankStephen BlankTim BlankEstate of Dorothy BlileyDave BloodSusan BorzenskiBryce BreitensteinJill BrennemanRobert BrineEstate of Curtis BrownPatricia BrownDona BrowneRona BudovitchEstate of Charles P. Bukowski
Estate of Sidney BullLander BurrRona CaplanEstate of Patricia CarneyJennifer ChristensenEstate of Steven ColtRuth ColtenPhil ConleyMichelle CovingtonLaura CridlebaughBetsy CulbersonPhil CulbersonEstate of Doris CurtisJohn DaytonEstate of Marie De BarbieriVera Deutsch
Members of the Founders Society give a precious gift to everyone who has Crohn’sdisease or ulcerative colitis: the promise that future generations will be spared thepain of these diseases.
The Society honors those who strengthen the vision and commitment of our foundersby including the Foundation in their will or estate plans. Founders Society Membersprovide for a healthy tomorrow in a variety of ways, such as making a bequest by inclusion of the Foundation in a will, charitable gift annuities, trusts, retirement plangifts, and insurance policy gifts.
The above is a limited sampling of how a legacy to benefit the Foundation may be accomplished. For more information, please visit our web site at www.ccfa.org/plannedgiving or contact the Planned Giving Department at [email protected] 800-932-2423. Please discuss with your attorney the means most appropriate for you. The Crohn’s & Colitis Foundation’s general counsel would also be happy to discuss with your attorney how best to accommodate your wishes.
The Crohn’s & Colitis Foundation gratefully acknowledges the foresight, generosity,and commitment of our Founders Society Members:
35
Founder’s Society
Carol DirksMary DiSantiEstate of David E. DrexlerEstate of Anna DruckEstate of Gerald W. DulkisKenneth DunstGeorgette EdkinsEstate of Elizabeth ErasmusMary Jane EvansEstate of Carol Rosenthal EzringEstate of Myron FeinbergKaren FindoraAlan FinnCarmen FiorelliEstate of Ruth FleisherWilliam FrankensteinEstate of James FranklinEstate of Mary FranklinJohanna FrerichsMichelle FriedmanBrenda FudellEstate of Ruth FurmanEstate of Jules FurthEstate of Catherine GadomskiArlene GalbertRobert GarmanEstate Of Charles GeistAnnette GilmanLeonard GilmanEstate Of Harry GoldDeborah P. GoldbergEstate of Henrietta GoldbergDiane GoldfarbDonald GoldfarbEstate of Phillip GoosMona GordonRandi GordonMiriam GottliebEstate Of Marion GouldMarcia GreenburgEstate of Clarence GregoryToby GreeneLorri GreifEstate of Robert GrierFanny GruszeckiLillian GuyBruce HartzmarkJudy HauserEstate of Richard HauserBob HawkMary Sue HawkDaniel HawkinsMichelle HendersonEstate of Frances M. HenryClifford HillDeanne HillHerbert and Bonita HirschHanna HombordyNancy HomeyerWilliam HomeyerGerald HonlSandra HonlEstate of Kathryn Ann JacklinEstate of Linda JellenikSharon Kahn
Estate of Sylvia KaplanAudrey KatzMark KaufmanDawne KaufmanJune KayLouis KayMilicent KellnerRita KendallEric LandauRenee LandauBeth Ann Landow-KingGloria LangosPatricia LaPedusDon LaRoccaKaren LaRoccaLouis LauerEstate of Bernard LeebEstate of Pauline LeibowIrma LeonArthur LevineJudith Ludwig LevineRonald LevyMichael LibysDavid LinemeyerLucia LodingAdeline LuckmanJuanita LudkeHarvey LutermanEstate of John LynchRusty MaddoxEstate of Sylvia MalawskyMarc MarascoMargaret MarascoEdna MarcusEstate of Frank and Alma Lee MarshallThomas MartinCarolyn MartinConstance L. MartinNancy McNabbHenry MeyerShelby ModellWilliam ModellCynthia MonterJohn MonterNoel MooreJ. Roger MorrisonMartha MorrisonPattie Moxham-FisherCharles MunseyBarb NiederBob Nieder Agnes NixonSteven PantosRenee ParenteFaye ParhamEleanore PattersonSantos PerezOscar PetersonEstate of George J. PiersonKathryn PizzaMaurice PloughChristine PollockMark C. Pope, IIIEstate of Rufus PorterRex Rathbun
Estate of Mary Ellen ReedyEstate of Abraham RichRosalyn RichmanCarol RobertsSeymour RobertsRobin RogerEstate of Burt RosenbergMona RosenbergIrwin RosenthalSuzanne RosenthalR. Warren RossArnold RudoffCarol RudoffPaul RussellSelma RyaveThe Judith Saphir Research FundDr. Richard SaphirRoberta SchecterBruce SchmittShirley SchreiberDr. Ronald SchwartzSusan SchwartzEstate of Blanche SelwynEstate of Herman SelwynCarol SextonRobert SextonRoslyn SherJudy SigalNettie R. SilvermanGeorge SmythSheldon SokolSeymour SperlingJohn SpieckerEstate of Anita StaufferSylvia SteinbrockEstate of Joseph SujanskyEstate of Ellen M. SullivanBeverly TaubelEugene TaubelJane ThomasJulie TownsendFelicia TraubMichael TronzoJeffery TupperRosemarie Van IngenJane VandermeerLawrence VandervoornVivian VandorSalvatore VarveriJames VaughanKathryn VaughanEstate of Adele VerkmanHelene VictorSara Jane VictorJeffrey WardRene WarrenJoseph WeiselArie WeissmanEstate of Evelyn WestbergRay WhitakerNancy WiltgenLinda WindsorJohn WineCharles YochimPhoebe Yochim
Our ChaptersALABAMAAlabama/Northwest Florida Chapter244 Goodwin Crest Drive, Suite 120Birmingham, AL 35209-3711Phone: (205) 941-9900Fax: (205) 941-1411Email Address: [email protected]
ARIZONASouthwest Chapter8098 Via De Negocio, Suite 201Scottsdale, AZ 85258Phone: (480) 246-3676Fax: (480) 246-3679Email Address: [email protected]
CALIFORNIAGreater Los Angeles Chapter1640 South Sepulveda Blvd., Suite 214Los Angeles, CA 90025Phone: (310) 478-4500Fax: (310) 478-4546Email Address: [email protected]
Greater San Diego and Desert AreaChapter
7850 Mission Center Ct. Ste. 100San Diego, CA 92108Phone: (619) 497-1300Fax: (619) 497-1304Email Address: [email protected]
Northern California Chapter5 Third St., Suite 625San Francisco, CA 94103Phone: (415) 356-2232Fax: (415) 356-0880Email Address: [email protected]
COLORADORocky Mountain Chapter1777 South Bellaire Street, Suite 230Denver, CO 80222-4310Phone: (303) 639-9163Fax: (303) 639-9166Email Address:
CONNECTICUTConnecticut ChapterP.O. Box 275Branford, CT 06405Phone: (203) 208-3130Email Address: [email protected]
FLORIDAFlorida Chapter21301 Powerline Rd., Suite 301Boca Raton, FL 33433Phone: (561) 218-2929Fax: (561) 218-2240Email Address: [email protected]
North Florida ChapterP.O. Box 14959Jacksonville, FL 32238-4959Phone: (646) 201-6468Fax: (904) 738-7216Email Address: [email protected]
GEORGIAGeorgia Chapter2250 North Druid Hills Road, Suite 250Atlanta, GA 30329-3118Phone: (404) 982-0616Fax: (404) 982-0656Email Address: [email protected]
IOWAIowa ChapterP.O. Box 1944Council Bluffs, IA 51502Phone: (847) 827-0404Email Address: [email protected]
ILLINOISIllinois Carol Fisher Chapter2200 East Devon Avenue, Suite 351Des Plaines, IL 60018-4509Phone: (847) 827-0404Fax: (847) 827-6563Email Address: [email protected]
INDIANAIndiana Chapter931 East 86th Street, Suite 210Indianapolis, IN 46240Phone: (317) 259-8071Fax: (317) 259-8091Email Address: [email protected]
KENTUCKYKentucky Chapterc/o Tennessee Chapter95 White Bridge Road, Suite 209Nashville, TN 37205Phone: (615) 356-0444Fax: (615) 356-0445Email Address: [email protected]
LOUISIANALouisiana/Mississippi Chapter7611 Maple Street, Suite BNew Orleans, LA 70118Phone: (504) 861-3433Fax: (504) 861-3466Email Address: [email protected]
MASSACHUSETTSNew England Chapter280 Hillside Avenue, Fl. 2, Ste. 9Needham, MA 02494-1365Phone: (781) 449-0324Fax: (781) 449-0325Email Address:
MARYLANDMaryland/Southern Delaware Chapter10400 Little Patuxent Parkway,
Suite 270Columbia, MD 21044Phone: (443) 276-0861Fax: (443) 276-0865Email Address: [email protected]
Our Chapters
37MICHIGANMichigan Chapter31313 Northwestern Highway, Suite 204Farmington Hills, MI 48334-2577Phone: (248) 737-0900Fax: (248) 737-0904Email Address: [email protected]
MINNESOTAMinnesota/Dakotas Chapter1885 University Avenue West, Suite 355St. Paul, MN 55104-3462Phone: (651) 917-2424Fax: (651) 917-2425Email Address: [email protected]
MISSOURIMid-America Chapter1034 S. Brentwood Blvd., Suite 1510St. Louis, MO 63117Phone: (800) 783-8006Fax: (314) 863-4749Email Address: [email protected]
NORTH CAROLINACarolinas Chapter2901 North Davidson Street, Suite 160Charlotte, NC 28205Phone: (704) 332-1611Fax: (704) 332-1612Email Address: [email protected]
NEBRASKANebraska Chapter1941 South 42nd Street, Suite 543Omaha, NE 68105-2939Phone: (402) 505-9901Fax: (402) 505-9931Email Address: [email protected]
NEW JERSEYNew Jersey Chapter45 Wilson AvenueManalapan, NJ 07726-1501Phone: (732) 786-9960Fax: (732) 786-9964Email Address: [email protected]
NEW YORKFairfield/Westchester Chapter200 Bloomingdale Road, 2nd FloorWhite Plains, NY 10605-1514Phone: (914) 328-2874Fax: (914) 328-2946Email Address: [email protected]
Greater New York Chapter386 Park Avenue South, 14th FloorNew York, NY 10016-8804Phone: (212) 679-1570Fax: (212) 679-3567Email Address: [email protected]
Long Island Chapter585 Stewart Avenue, Suite 580Garden City, NY 11530-4701Phone: (516) 222-5530Fax: (516) 222-5535Email Address: [email protected]
Rochester, New York/Southern Tier Chapter2117 Buffalo Road, Suite 299Rochester, NY 14624Phone: (585) 617-4771Fax: (585) 617-4771Email Address: [email protected]
Upstate/Northeastern New York Chapter4 Normanskill Blvd.Delmar, NY 12054Phone: (518) 608-5069Email Address: [email protected]
Western New York Chapter2714 Sheridan DriveTonawanda, NY 14150Phone: (716) 833-2870Fax: (716) 783-7899Email Address: [email protected]
OHIOCentral Ohio Chapter5008 Pine Creek Drive, Suite AWesterville, OH 43081Phone: (800) 625-5977Fax: (614) 865-1934Email Address: [email protected]
Northeast Ohio Chapter23775 Commerce Park RoadBeachwood, OH 44122Phone: (866) 345-2232Fax: (216) 831-2792Email Address: [email protected]
Southwest Ohio Chapter8 Triangle Park Drive, Suite 800Cincinnati, OH 45246Phone: (877) 283-7513Fax: (513) 772-7599Email Address: [email protected]
OKLAHOMAOklahoma Chapterc/o North Texas Chapter12801 North Central Expressway, Suite 270Dallas, TX 75243Phone: (918) 523-8540Fax: (972) 386-0509Email Address: [email protected]
PENNSYLVANIAPhiladelphia/Delaware Valley Chapter367 East Street RoadTrevose, PA 19053-7711Phone: (215) 396-9100Fax: (215) 396-1170Email Address: [email protected]
Western Pennsylvania/West Virginia Chapter
300 Penn Center Boulevard, Suite 401Pittsburgh, PA 15235Phone: (877) 823-8272Fax: (412) 823-8276Email Address: [email protected]
TENNESSEETennessee Chapter95 White Bridge Road, Suite 209Nashville, TN 37205Phone: (866) 814-2232Fax: (615) 356-0445Email Address: [email protected]
TEXASHouston Gulf Coast/South Texas Chapter5120 Woodway, Suite 8008Houston, TX 77056-1758Phone: (800) 785-2232Fax: (713) 572-2433Email Address: [email protected]
North Texas Chapter12801 North Central Expressway, Suite 270Dallas, TX 75243Phone: (972) 386-0607Fax: (972) 386-0509Email Address: [email protected]
VIRGINIAGreater Washington, D.C./Virginia Chapter4085 Chain Bridge Rd., Suite 201Fairfax, VA 22030Phone: (877) 807-5271Fax: (703) 865-8873Email Address: [email protected]
WASHINGTONNorthwest Chapter9 Lake Bellevue Drive, Ste. 203Bellevue, WA 98005Phone: (877) 703-6900Fax: (425) 451-1708Email Address: [email protected]
WISCONSINWisconsin Chapter1126 S. 70th Street, Suite S210AWest Allis, WI 53214Phone: (877) 586-5588Fax: (414) 475-5502Email Address: [email protected]
Leadership & StaffOFFICERS
Mark GoldmanChair of the National BoardWeston, MA
Jonathan Braun, M.D., Ph.D.Chair, National Scientific Advisory
CommitteeLos Angeles, CA
Gary SinderbrandChair-Elect of the National BoardLinwood, NJ
Bernard Eizen, Esq.General CounselPhiladelphia, PA
Louis PlungTreasurerPittsburgh, PA
Richard KleinmanSecretarySyosset, NY
IMMEDIATE PAST CHAIR
Eugene KestenbaumImmediate Past Chair of the
National BoardHuntingdon Valley, PA
TRUSTEES
David AlbergaLa Jolla, CA
Richard S. Blumberg, M.D.Boston, MA
Kenneth EdmondsSilver Spring, MD
Arthur FalconeBoca Raton, FL
George Ferry, M.D.Houston, TX
Lawrence FinkelsteinPhiladelphia, PA
Sanford J. Grossman, Ph.D.Greenwich, CT
Michael J. KossMilwaukee, WI
Joel H. MargoleseAndover, MA
Henry MordohPittsburgh, PA
Susan N. Peck, M.S.N., C.R.N.P.Wynnewood, PA
David A. Piccoli, M.D.Philadelphia, PA
Marysue WechslerFairfax, VA
Leadership & Staff
39CHAIRS EMERITI1967 to present
*Irwin M. Rosenthal, Riverdale, NY** William D. Modell (deceased)Irving Rubin (deceased)Lynn Meyerhoff (deceased)Stephen Blank, Watchung, NJSuzanne Rosenthal, Riverdale, NYJane W. Present, New York, NYMorgan K. Powell, Collinsville, OKRobert A. Brine, Edmonds, WAScott R. Allswang, Phoenix, AZLisa H. Richardson, Houston, TX*Founding President
**Founding Chair
HONORARY BOARD MEMBERSCo-foundersIrwin M. Rosenthal and Suzanne
RosenthalWilliam D. Modell (deceased)
and Shelby ModellHenry D. Janowitz, M.D. (deceased)
MembersScott R. Allswang, Phoenix, AZTheodore Bayless, M.D., Baltimore, MDRolf J. Benirschke, San Diego, CAStephen Blank, Watchung, NJEdgar Cullman, Jr., New York, NYJoel Cutler, Boston, MATheodore and Joan Cutler, Needham, MACharles O. Elson, M.D., Birmingham, ALDiane Goldman, Weston, MAKurt J. Isselbacher, M.D., Charlestown, MAEugene A. Kestenbaum, Huntingdon
Valley, PAJoseph B. Kirsner, M.D., Ph.D., Chicago, ILBurton I. Korelitz, M.D., New York, NYEsther Kusher (deceased)Donald and Mary Jo Lenauer, Owensville,
MORichard P. MacDermott, M.D., Albany, NYJeffrey Mankoff, Dallas, TXMichael McCready, Seattle, WATrish McEvoy, New York, NYLynn Meyerhoff (deceased)Mary Ann Mobley and Gary Collins,
Beverly Hills, CAMichael Modell (deceased)Peter Nielsen, Commerce, MIMandy Patinkin, New York, NYMarsha Patinkin (deceased)Donald Pray, Tulsa, OKLisa Richardson, Houston, TXIrving Rubin (deceased)Judy Saphir (deceased)R. Balfour Sartor, M.D., Chapel Hill, NCStephan R. Targan, M.D., Los Angeles, CA
NATIONAL SCIENTIFIC ADVISORYCOMMITTEE
CHAIRS EMERITI
Richard S. Blumberg, M.D.Immediate Past ChairpersonProfessor of MedicineChief, Gastroenterology DivisionBrigham & Women’s Hospital Boston, MA
Theodore M. Bayless, M.D.Professor of Medicine, Sherlock HibbsProfessor of IBDDirector, Meyerhoff Digestive Disease
and IBD CenterThe Johns Hopkins Medical InstitutionsBaltimore, MD
Charles O. Elson, M.D.Basil I. Hirschowitz Chair in GastroenterologyProfessor of Medicine and MicrobiologyVice-Chair for Research, Department
of MedicineUniversity of Alabama at BirminghamBirmingham, AL
Kurt J. Isselbacher, M.D.Massachusetts General Hospital
Cancer CenterMallinckrodt Distinguished Professor
of MedicineBoston, MA
Henry D. Janowitz, M.D. (deceased)
Joseph B. Kirsner, M.D., Ph.D.Louis Block Distinguished Service
Professor of MedicineThe University of ChicagoChicago, IL
Burton I. Korelitz, M.D.Chief of Gastroenterology, EmeritusDirector of Research in IBDLenox Hill HospitalProfessor of Medicine, NYU School of MedicineNew York, NY
Richard P. MacDermott, M.D.Thomas Ordway Endowed ChairAlbany Medical CollegeAlbany, NY
R. Balfour Sartor, M.D.Professor of Medicine, Microbiology,
and ImmunologyUniversity of North Carolina at Chapel HillChapel Hill, NC
Stephan R. Targan, M.D.Director, Cedars-Sinai Division of
GastroenterologyDirector, Cedars-Sinai
Inflammatory Bowel Disease CenterFeintech Family Foundation Chair
in Inflammatory Bowel DiseaseCedars-Sinai Medical CenterProfessor, UCLA School of MedicineLos Angeles, CA
NSAC COMMITTEE
Jonathan Braun, M.D., Ph.D.Chair, NSACProfessor, Geffen School of Medicine UCLA Medical CenterChair, Department of Pathology
& Lab MedicineLos Angeles, CA
Richard S. Blumberg, M.D.Immediate Past ChairpersonProfessor of MedicineChief, Gastroenterology DivisionBrigham & Women’s HospitalBoston, MA
John A. Barnard, M.D.Liaison, North American Society of Pediatric
Gastroenterology Hepatology, and Nutrition (NASPGHAN)
Professor, PediatricsOhio State UniversityColumbus, OH
Robert Burakoff, M.D.Chair, Editorial BoardClinical Chief, Division of GastroenterologyBrigham & Women’s HospitalBoston, MA
Sean Colgan, Ph.D.Chair, Research Training AwardsUniversity of Colorado Health Sciences CenterKern Professor of MedicineDirector, Mucosal Inflammation PgmDenver, CO
Victor W. Fazio, M.D.Liaison, Surgical AffairsColorectal Surgery Department ChairThe Cleveland ClinicCleveland, OH
Stephen P. James, M.D.Liaison, National Institutes of HealthDirector, Division of Digestive Diseases
and NutritionNational Institute of Diabetes and Digestive
and Kidney DiseasesNational Institutes of HealthBethesda, MA
Uma Mahadevan-Velayos, M.D.Chair, Patient EducationAssistant Clinical Professor of MedicineUniversity of California San FranciscoSan Francisco, CA
Susan N. Peck, R.N.Liaison, Nursing AffairsChildren’s Hospital of Philadelphia Division of GastroenterologyPhiladelphia, PA
John D. Rioux, Ph.D.Chair, DNA/Cell Line BankAssociate Professor of MedicineMontreal Heart InstituteMontreal, Quebec
David Rubin, M.D.Chair, Professional EducationAssistant Professor, GastroenterologyUniversity of ChicagoChicago, IL
Bruce E. Sands, M.D., M.P.H.Chair, Clinical Research AllianceAssociate Professor of MedicineHarvard Medical SchoolMassachusetts General HospitalBoston, MA
Joseph H. Sellin, M.D.Liaison, Professional AffairsDirector, C2-CREATE IBD CenterDivision of Gastroenterology, UTMBGalveston, TX
William F. Stenson, M.D.Chair, Research InitiativesProfessor of MedicineWashington University Medical Center Division of GastroenterologySt. Louis, MO
Francisco Sylvester, M.D.Chair, Pediatric AffairsAssistant Professor, PediatricsConnecticut Children’s Medical Center Division of Gastroenterology & NutritionHartford, CT
Stephan R. Targan, M.D.Chair, Grants CouncilDirector, Cedars-Sinai Division of
Gastroenterology and IBD CenterProfessor, UCLA School of MedicineLos Angeles, CA
Casey T. Weaver, M.D.Chair, Grants ReviewProfessor of Pathology and MicrobiologyUniversity of Alabama at BirminghamBirmingham, AL
NATIONAL OFFICE STAFF LEADERSHIP
Richard J. GeswellPresident
R. Balfour Sartor, M.D.Chief Medical Advisor
Michael J. Galvin, CPA Chief Operating Officer/Chief Financial Officer
Judith Arner BrownVice President of Chapter Services/Revenue Generation
Kimberly FrederickVice President of Patient, Professional &Educational Services
Marjorie MerrickVice President of Research & ScientificPrograms
Marie GranieriSenior Director of Marketing
Stacy ParmeleSenior Director of Human Resources
A future free from Crohn’s and colitis.
Our Vision
National Office386 Park Avenue South, 17th FloorNew York, NY 10016-8804
800.932.2423212.685.3440
Web site: www.ccfa.orgE-mail: [email protected]